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INTRODUCTION 
 Systemic lupus erythematosus (SLE) is an autoimmune disease, with a wide 
range of clinical manifestations. In 1976, Urowitz et al. (1) postulated a bimodal 
mortality pattern in patients with this disease: in the first part of evolution, mortality 
is due to severe infections or to disease activity, but after 5 years of SLE course, 
mortality is caused by the accelerated atherosclerosis and its consequences. With the 
constantly increasing drugs available in the therapeutic armamentarium, even though 
the early mortality has been brought under control, the late mortality and morbidity 
associated with SLE remains at high levels. During the last 3 decades, there have 
been several studies on atherosclerosis in SLE. It has been proved that 
atherosclerosis has a high incidence among young women with SLE. These patients 
have a high prevalence of coronary artery disease and an incidence of myocardial 
infarction up to 50 times higher than age-matched healthy subjects. This high 
incidence of atherosclerosis in SLE cannot be attributed only to traditional risk 
factors (2, 3). 
 Endothelial function is thought to be an important factor in the pathogenesis 
of atherosclerosis, hypertension and heart failure. In healthy subjects, endothelium is 
more than a physical barrier and has several functions, like: a) continuous regulation 
of vascular tone, b) leucocytes adhesion, c) maintenance of the balance between 
thrombotic and anticoagulant properties of the blood (4). When these functions of 
the endothelium are affected, endothelial dysfunction appears. 
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 Endothelial dysfunction is considered as the first step in the atherogenetic 
process. Endothelial dysfunction in SLE is produced by the clustering of traditional 
risk factors, adverse effects of treatment and SLE itself as an independent risk factor 
(5, 6). Systemic inflammation, autoantibodies directed to double stranded DNA 
(dsDNA), ribonucleoproteins (nRNP), endothelial cells, phospholipids, circulating 
immune complexes, activated complement products, lupus nephropathy and 
dyslipidemia represent some factors related to SLE which contribute to appearance 
of endothelial dysfunction (7,8). In the 1990s, high-frequency ultrasonographic 
imaging of the brachial artery to assess endothelium-dependent flow-mediated 
vasodilatation (FMD) was developed. The technique provokes the release of nitric 
oxide, resulting in vasodilatation that can be quantitated as an index of vasomotor 
function. The noninvasive nature of the technique allows repeated measurements 
over time to study the effectiveness of various interventions that may affect vascular 
health (9).  
 Tremendous interest exists in determining the clinical utility of brachial 
artery FMD. Investigators have hypothesized that endothelial function may serve as 
an integrating index of risk factor burden and genetic susceptibility, and that 
endothelial dysfunction will prove to be a preclinical marker of cardiovascular 
disease (10). Several studies suggest that the presence of endothelial dysfunction in 
the coronary circulation is an independent predictor of cardiovascular disease events 
(11, 12). The technique is particularly well suited for study of the earliest stages of 
atherosclerosis in children and young adults, thus providing maximal opportunity for 
prevention. Recently, endothelial dysfunction has also been found in patients with 
systemic vasculitis and has been reversed by administration of immunosuppressive 
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therapy (13). As endothelial dysfunction may represent an early stage in 
atherogenesis, it is important to understand the mechanisms of its development in a 
condition such as SLE. It is also important to determine whether it is associated with 
other CHD risk factors or early atheroma.  
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REVIEW OF LITERATURE 
 SLE predominantly occurs in women, with a gender ratio of 9:1. Onset is 
typically in the age group of 20- 30 yrs. Multiple predisposing factors have been 
identified. The genetic predisposition is complex, likely involving more than 100 
genes. HLA-DR and DQ alleles are associated not just with the risk of developing 
lupus, but with the kinds of autoantibodies produced. Genes that control apoptosis 
(programmed cell death) are important in murine lupus models and likely in human 
lupus as well. The proteins to which the lupus patient mounts an autoantibody 
response are exposed on nuclear blebs during apoptosis. Genes involved in immune 
complex clearance (Fc-gamma receptor alleles) may predispose patients to lupus 
nephritis. Gene expression studies have identified an "interferon signature"—a 
group of genes regulated by interferon-—in the majority of SLE patients. The 
genetic predisposition to SLE is not overwhelming. Only 10% of patients have a 
first-degree relative with SLE, and SLE develops in only 2% of children who have 
an afflicted parent. 
 Environmental factors play a role not only in the onset of SLE but also in 
triggering the "flares" (relapses). The most recognized environmental trigger is 
ultraviolet light exposure. Ultraviolet (UV) light significantly by UV - B can trigger 
photosensitive rashes, and more rarely, systemic flares. SLE patients are more likely 
than controls to have drug allergies, especially to sulfonamide antibiotics. Infection 
with Epstein-Barr virus has been strongly associated with SLE in a multicase family 
registry. Hormonal factors are obviously important, given the female predominance 
of SLE and the usual onset of SLE after puberty. In clinical trials, hormone 
                                                      
 
12
replacement therapy has been associated with increased flares in SLE, but oral 
contraceptives did not. Pregnancy is associated with SLE flares in some, but not all, 
studies. Elevation of prolactin may be associated with activity of SLE. 
 The activity of SLE follows several patterns. The classic pattern, the flare 
pattern, is characterized by a relapsing-remitting course. However, an equal number 
of SLE patients have a pattern of continuously active disease. Only a minority of 
patients have long periods of disease quiescence. The antimalarial drug 
hydroxychloroquine, which is widely used for cutaneous lupus and lupus arthritis, 
reduces future flares if patients continue to take it. Over half of SLE patients have 
acquired permanent damage in one or more organ systems. Although damage, such 
as renal failure and interstitial pulmonary fibrosis, can occur from SLE itself, 
immunosuppressive therapy also contributes to certain damage. For example, long-
term prednisone therapy may cause osteoporotic fractures, osteonecrosis, cataracts 
and glaucoma. 
 Survival of SLE patients peaked at about 80% at 10 years after diagnosis in 
the 1980s. The Centers for Disease Control and Prevention reported in 2002 that 
mortality in young women had actually increased. The major cause of death in SLE 
is accelerated atherosclerosis. Although SLE itself can damage the endothelial 
surface of the coronary arteries, part of the atherosclerotic process results from 
elevated levels of traditional cardiovascular risk factors, including hypertension, 
dyslipidemia, obesity, and homocysteine levels. Prednisolone increases the patient's 
weight, blood pressure, glucose, and lipid levels. SLE nephritis can lead to 
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hypertension and dyslipidemia. Renal insufficiency can increase serum 
homocysteine levels. 
 The description of a bimodal mortality pattern in SLE patients by Urowitz  
et al. in 1976 was an instrumental step toward identifying their increased risk of 
premature atheromatous cardiovascular disease (CVD). Patients who succumbed to 
lupus early in the disease course were noted to die most often from complications of 
disease activity (e.g., organ failure) or therapy. Patients who died later often had 
quiescent disease, and died from CV events. These findings were substantiated by an 
autopsy series reported by Bulkey et al. in which the majority of a cohort of young 
women with a mean age of 35 years had significant obstructive atherosclerotic 
disease of at least one major coronary artery (14). As survival has improved from 
better means of disease detection and treatment, atherosclerotic CVD has emerged 
as a significant cause of morbidity and mortality in SLE. The prevalence of 
cardiovascular and cerebrovascular events in SLE ranges from 6% to 26% (15, 16, 
17, 18, 19, 20, 21, 22, 23 & 24). Ischemic cerebrovascular events (stroke/transient 
ischemic attack) have been reported in 10% to 26%, (17, 18, 22, 23 & 24), whereas 
MI and angina have been reported in 6% to 11% of SLE patients (15, 16, 19, 20, 21, 
22, 23 & 24). 
 Not surprisingly, autopsy studies as well as the examination of surrogate 
markers of coronary atherosclerosis in SLE suggest that the prevalence of 
subclinical atherosclerosis is higher than overt events (14, 25, 26, 27, 28, 29, 30, 31, 
32, 33, 34, 35 & 36). Autopsy studies reveal atherosclerotic disease of the coronary 
arteries in SLE in 22% to 54% of cases (14, 25 & 26). Noninvasive studies 
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including vascular ultrasound, electron beam tomography, and myocardial perfusion 
studies demonstrate atherosclerotic vascular disease in 17% to 40% of SLE patients 
(27, 28, 29, 30, 31, 32, 33, 34, 35 & 36). In a cohort of SLE women with a mean age 
of 44.9 years, 40% were found to have focal carotid plaque as measured by 
ultrasound (27). Another study of 75 SLE women with a mean age of 38.8 years 
demonstrated that 28% had coronary artery calcifications (31). Roman et al. found 
carotid plaque in 37% of SLE patients, compared with a prevalence of 15% in age, 
sex, and race-matched controls (32). 
 A striking feature of this comorbid condition of SLE is its predilection for 
premenopausal women. Ward evaluated rates of hospitalization for cardiovascular 
events in a cohort of SLE women compared to a control group (37). Younger SLE 
women (age 18 to 44) were 2.27 times more likely to be hospitalized with MI and 
3.8 times more for congestive heart failure than controls. In the middle-aged women 
(45 to 64 years), the frequency of hospitalization for heart failure was just 1.39 times 
higher, and the frequency for MI hospitalization did not differ significantly from that 
of controls. A study comparing SLE women with age-similar women from the 
Framingham offspring cohort demonstrated a 50-fold increased risk of MI in the 
SLE women between 35 and 44 years of age (38). In sharp contrast to women in the 
general population, where the risk of atherosclerotic CV events is highest after 
menopause, the mean age at the first event in SLE women was earlier in their life 
(39). 
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 Traditional risk factors for CVD occur frequently in SLE, both as a 
consequence of disease activity and treatment. The presence of subclinical 
inflammation in the general population has been demonstrated to correlate with the 
development of a number of traditional risk factors, including insulin resistance, 
visceral adiposity and hypertension (40, 41 & 42). It is possible that the sustained 
systemic inflammation and immune activation in SLE has similar influences on the 
development of CV risk factors. The Toronto Risk Factor Study compared 250 SLE 
patients with 250 controls and found that SLE patients had a higher number of CV 
risk factors per patient as well as a higher prevalence of diabetes, hypertension, and 
elevated levels of low-density lipoproteins, triglycerides, and homocysteine (43). 
Additionally, both Bruce et al. and Costenbader et al. have demonstrated that even 
when CV risk factors are identified in SLE patients, they often are not adequately 
treated (44,45). Although a large part of CVD risk in SLE is likely a result of a high 
prevalence of traditional CV risk factors, Esdaile et al. demonstrated that the 
presence of CV risk factors alone does not explain the increased incidence of CV 
events (46). 
 Glucocorticoid therapy has been implicated in atherosclerosis in both lupus 
and nonlupus patients, but it is unclear whether this reflects pro-atherogenic effects 
of the underlying disease process or adverse metabolic effects associated with 
steroid use (47, 48, 49). 
 Antiphospholipid antibodies have been considered as a contributory factor to 
SLE-associated atherosclerotic disease. In addition to their postulated role in arterial 
endothelial damage, they have been associated with renal arterial disease (both 
                                                      
 
16
thrombotic and stenotic), which may result in hypertension from activation of the 
renal-angiotensinogen-aldosterone axis from renal hypoperfusion (50, 51). Although 
cohort studies have failed to identify an association between the presence of 
antiphospholipid antibodies and surrogate markers of coronary atherosclerosis, there 
is a strong association between surrogate markers of CVD and CV events with 
hypertension with in SLE (22, 52 and 53). The importance of this association 
becomes apparent when more closely evaluated.  
 Cardiovascular disease and atherosclerosis are a common cause of morbidity 
and mortality in various SLE cohorts. Autopsy studies from the early 1980s showed 
severe atherosclerosis in 40% of SLE patients compared with 2% of control subjects, 
matched for age at the time of death. Analysis of the Swedish Hospital Discharge 
Register followed by linkage to the Cause of Death Register during the period 1964 
to 1995 showed that SLE patients were at increased risk for death as a result of 
coronary heart disease or stroke (standardized mortality ratio 2.97, 95% confidence 
interval 2.78 to 3.16). The risk was substantially higher in the younger group of 
patients (20 to 39 years old; standardized mortality ratio 16, 95% confidence interval 
10.4 to 23.6). 
 Other studies have shown that SLE patients carry an increased risk for 
myocardial infarction or stroke compared with the healthy population. This risk 
cannot be fully explained by the traditional cardiovascular disease risk factors.  
Atherosclerosis—defined by coronary artery calcification or carotid plaque size—
also is more common in SLE patients than in healthy controls (e.g., 31% versus 9%, 
in subjects with an average age of 40; relative risk 9.8, 95% confidence interval 2.5 
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to 39), even after adjustment for possible confounding factors, and it correlates with 
disease activity and damage scores.  
Pathogenesis of coronary atherosclerosis in SLE: 
Immune Complex or Arteritis 
 Animal models suggest that this contributes to atherosclerosis. Vascular 
injury, through immune complexes, followed by exposure to atherosclerotic risk 
factors, can lead to atherosclerosis in animal models. Immunization of rabbits with 
heat-shock protein 60/65 leads to aortic intima atherosclerosis. Coronary 
vasculopathy and myocardial infarctions are found in murine lupus models, often in 
association with anticardiolipin antibody. Immune complexes from lupus sera 
accelerated uptake of cholesterol by smooth muscle cells. One small study in human 
SLE suggested that patients treated with corticosteroids had less intimal proliferation 
in their coronary vessels, suggesting that suppression of arteritis initially might lead 
to less atherosclerosis later. 
Anti-phospholipid Antibodies 
 Anti-phospholipid antibodies could contribute to coronary artery disease 
through thrombosis or vasculopathy. The association of anti-phospholipid antibodies 
with coronary artery disease has been shown in some but not all studies. It has been 
found that the lupus anticoagulant is associated with angina/myocardial infarction, 
but not carotid plaque. Lupus anticoagulant was increased in SLE cases with 
cardiovascular disease vs those without. Anti-phospholipid antibodies may function 
also as antibodies against oxidized lipoproteins, an additional mechanism (the 
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“oxidative modification hypothesis”) by which they might contribute to 
atherosclerosis. In one study, anti-oxLDL was higher in SLE cases with 
cardiovascular disease. However, several studies have failed to find an association of 
antioxLDL with arterial thrombosis, arterial disease or atherosclerosis. Finally, one 
of the plasma protein targets of antiphospholipid antibodies, b2 glycoprotein I, may 
be an important control against atherosclerosis that is perturbed by anti-phospholipid 
antibodies. Anti-b2 glycoprotein I accelerates uptake of oxLDL in vitro. There is 
also interest in lysophosphatidycholine, LPC, a high-affinity ligand for G2A, a 
lymphocyte expressed protein-coupled receptor. Genetic deletion of the receptor 
results in autoimmunity. LPC is reduced in SLE and anti-LPC has been detected.  
Chronic Infection 
 In the non-SLE patient, there is great interest in chronic infections, including 
Chlamydia pneumoniae, as potential causes of atherosclerosis. Simple antibiotic 
regimens could conceivably eliminate these infections and reduce later coronary 
artery disease. Whether these chronic infections lead to accelerated atherosclerosis 
in SLE is currently unknown. 
Coronary Artery Disease Risk Factors 
 Multiple studies have now proven that the risk of coronary artery disease 
(CAD) in SLE cannot be solely explained by traditional cardiovascular risk factors. 
After controlling for common risk factors at baseline, SLE patients have a relative 
risk of 10.1 for nonfatal MI. In a study with control subjects matched for traditional 
cardiovascular risk factors, SLE patients had more carotid atherosclerosis (41 vs 
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9%) and left ventricular hypertrophy (32 vs 5%). On average, SLE patients with 
coronary artery disease have one less traditional cardiovascular risk factor than a 
control patient. Although traditional risk factors cannot explain all atherosclerosis in 
SLE, they contribute significantly to the process.  
 Several works have found that routine coronary artery disease risk factors are 
very frequent in SLE patients. In fact, the average SLE patient in a cohort study has 
3 or more of these routine CAD risk factors. Some of these risk factors could be due 
to SLE. Hypertension, for example, is more prevalent in SLE patients with renal 
disease. Hypertension is associated with coronary artery disease in SLE, including 
some, but not all, multivariate analyses.  
 Hyperlipidemia in SLE has two major patterns. One pattern occurs in active 
disease, especially in pediatric patients. These patients have low HDL cholesterol 
and apoprotein A1 with elevated VLDL cholesterol and triglyceride levels. Lahita 
and colleagues have found a similar dyslipoproteinemia in SLE patients with anti-
cardiolipin antibody. However, one group has found that disease activity, rather than 
anti-cardiolipin, explains the reduction in HDL. There are likely defects in early 
cholesterol transport and VLDL metabolism associated with active SLE. The second 
pattern occurs in SLE patients on corticosteroids, with higher levels of triglyceride, 
cholesterol, and LDL cholesterol. Sustained hypercholesterolemia, rather than 
baseline, or intermittent elevation, is the most important predictor. A third problem 
identified is decreased lipolysis and chylomicron remnant removal. Lipoprotein (a) 
(Lpa) has been identified as a risk factor for atherosclerosis in SLE. SLE patients 
can make anti-lp (a). Lp (a) may rise with disease flares and be reduced by 
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corticosteroids. SLE patients with higher lp (a) levels also have more immune 
complexes containing b2 glycoprotein I.  
 The major cause of death in lupus nephritis patients is cardiovascular 
disease. Traditional cardiovascular risk factors, especially hypertension and 
hyperlipidemia, are increased. Tubulointerstitial lipid deposits can be found. In 
juvenile-onset SLE, nephrotic range proteinuria is the strongest risk factor for 
atherosclerosis. In a longitudinal study, three CAD risk factors, weight, cholesterol, 
and mean arterial pressure, were worsened by prednisone therapy. In the regression 
model, a 10-mg increase in prednisone led to a 5.5-lb increase in weight and an 8.9-
mg% increase in total cholesterol, adjusting for all other factors known to affect 
these risk factors. Thus, even if the development of these CAD risk factors is 
directly due to SLE, prednisone treatment increases their levels.  
 A recent work has focused on a newly identified risk factor for 
cardiovascular disease, homocysteine. Homocysteine is an amino acid that has a 
direct toxic effect on endothelium and indirect effects, including induction of a 
vascular endothelial cell activator, promotion of vascular smooth muscle 
proliferation, and an inhibitory effect on endothelial cell growth. 
Hyperhomocysteinaemia has been shown to increase the risk of coronary artery 
disease, stroke, and carotid artery stenosis in the Physicians’ Health Study and the 
Framingham Heart Study. In the Hopkins Lupus Cohort Study, 15% of the 337 SLE 
patients had elevated homocysteine. Raised homocysteine levels were significantly 
associated with stroke and arterial thrombosis. A retrospective study has confirmed 
this association. 
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Based on several studies the risk factor frequency can be approximated as follows: 
Risk factor Frequency (%) 
Family history 41 
Hypertension 48 
Hypercholesterolemia 56 
Obesity (major) 38 
Smoking—ever 56 
Smoking—current 35 
Sedentary lifestyle 70 
Diabetes 7 
Homocysteine 15 
 
 Inflammation plays a major role in the pathogenesis of atherosclerosis and 
myocardial infarction in the general population. The benefit of statins, for example, 
is mediated not just by their lipid-lowering effect, but by an anti-inflammatory effect 
(demonstrated by reduction in C-reactive protein) that likely stabilizes plaques. In 
the general population, C-reactive protein, IL-6, fibrinogen, and other markers of 
inflammation are predictive of atherosclerosis. In SLE, C-reactive protein was not 
predictive in a multivariate model nor in univariate analyses in one lupus cohort. 
However, in another case-control study, C-reactive protein was increased in SLE 
cases vs SLE controls. They did not find fibrinogen to be predictive of 
atherosclerosis. In one study, fibrinogen increased with duration of disease 
regardless of disease activity, and was increased in SLE patients with thrombosis.  
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 Prolonged corticosteroid therapy could precipitate atherosclerosis indirectly, 
by increasing the levels of CAD risk factors (hypertension, hypercholesterolemia, 
hypertriglyceridemia, diabetes mellitus, obesity, and homocysteinemia) or directly, 
via vascular injury. Accelerated atherosclerosis has occurred in SLE patients without 
corticosteroid use, but such cases are very rare. In a 1986 review, Nashel made a 
strong case that the latter occurs. In animals, corticosteroids and ACTH produce 
vascular injury, alter vascular connective tissue and worsen experimentally induced 
atherosclerosis. Patients with Cushing’s syndrome, before effective treatment was 
available, commonly developed accelerated atherosclerosis. 
Flow mediated Dilatation:  
 The capacity of blood vessels to respond to physical and chemical stimuli in 
the lumen confers the ability to self-regulate tone and to adjust blood flow and 
distribution in response to changes in the local environment. Many blood vessels 
respond to an increase in flow, or more precisely shear stress, by dilating. This 
phenomenon is designated FMD. A principal mediator of FMD is endothelium-
derived NO. The precise mechanisms for the acute detection of shear forces and 
subsequent signal transduction to modulate vasomotor tone are not fully understood. 
The endothelial cell membrane contains specialized ion channels, such as calcium-
activated potassium channels, that open in response to shear stress (54, 55 & 56). 
The effect of potassium channel opening is to hyperpolarize the endothelial cell, 
increasing the driving force for calcium entry (there are no voltage-gated calcium 
channels in endothelial cells). Calcium activates an enzyme, endothelial nitric oxide 
synthase (eNOS), and the subsequent generation of NO appears to account for FMD 
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(57, 58). Indeed, endothelial denudation or treatment with a nitric oxide synthase 
(NOS) inhibitor abolishes FMD in a variety of arterial vessels. However, it was 
recently shown that blood vessels from mice genetically engineered to lack the 
eNOS enzyme (eNOS knockout mice) still respond to shear stress by dilating. In the 
eNOS knockout mice, FMD seems to be mediated by endothelium-derived 
prostanoids, as it is blocked by indomethacin (59). Thus, there is some redundancy 
in the system, and more than one endothelial mediator is capable of acting as the 
signal between endothelium and smooth muscle. It is unknown whether other 
mediators, such as the putative endothelium-derived hyperpolarizing factor, can 
cause FMD if both NO and prostanoids are deficient.  
 Several mechanisms may underlie the increase in NO in response to changes 
in shear stress. Very acute changes may be mediated by the increase in intracellular 
calcium that occurs when ion channels open (see the previous text). Over slightly 
longer time periods (minutes), shear-stress-induced phosphorylation of eNOS via a 
serine/threonine protein kinase, Akt/PKB, increases eNOS activity, even at low 
calcium concentrations, and this may be important to allow continued output of NO 
(60, 61). In addition, other posttranslational modifications of the enzyme 
(myristilation or palmitoylation) or interaction with caveolin can affect intracellular 
localization of the enzyme and thereby alter its function. Over longer time periods 
(many minutes or hours), eNOS gene transcription is activated, and this can result in 
continued increases in NO generation if shear stress is maintained at high levels.  
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 To assess endothelial function noninvasively, brachial arteries are scanned 
with high resolution ultrasound imaging, under baseline conditions (at rest) and 
during hyperemia induced by inflation and deflation of a sphygmomanometer cuff 
mostly around the forearm distal to the site to be scanned with ultrasound. The 
induced shear stress caused by the increased blood flow following transient ischemia 
induces nitric oxide (NO) release, which in turn causes local arterial vasodilatation. 
Endothelial function, defined as flow mediated dilatation (FMD), is estimated as the 
percentage increase in vessel diameter from baseline conditions to maximum vessel 
diameter during hyperemia. Impaired endothelial function of the brachial artery 
assessed in this manner has been reported in asymptomatic children and adults with 
elevated cardiovascular risk factors such as smoking (62), hypercholesterolemia 
(63), hypertension (64), diabetes mellitus (65), and hyperhomocysteinaemia (66). 
Although the results of these studies are likely to be internally valid, comparison of 
the FMD values across studies is troublesome. FMD values vary considerably across 
populations, ranging from –1.9 to 19.2%.  
 Masoud El-Magadmi et al (67) studied 62 women with SLE (1997 revised 
criteria) and 38 healthy women. Demographic and risk factor data were collected. In 
patients, disease activity and treatment-related parameters were also assessed. 
Endothelial function was assessed by flow-mediated dilation (FMD) in the brachial 
artery in response to reactive hyperemia. Carotid intima-media thickness (IMT) and 
the presence of carotid plaques were also assessed in SLE patients. FMD was 
impaired in SLE patients (median, 3.6%; range, –6.3% to 13.7%; versus median, 
6.9%; range, –6.6% to 17.8%, P<0.01). Using multiple regression analysis that 
included all subjects in which they retained all the classic CHD risk factors, they 
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found that systolic blood pressure (P=0.019) and SLE (P=0.017) were significantly 
associated with impaired FMD. Within SLE patients, IMT showed a negative 
correlation with percent FMD (r=–0.37, P<0.01). In stepwise multiple regression of 
SLE patients only, that also included SLE factors and IMT, IMT alone was 
independently associated with FMD (P=0.037).  Two other studies have reported 
similar findings. In a study from Sao Paulo, Lima et al noted that the mean± SD 
FMD in SLE was 5.0±5.0% compared with 12.0±6.0% in healthy control subjects. In 
this study, postmenopausal women and subjects with known CHD risk factors were 
excluded. Piper et al found in a UK cohort that SLE women had a median FMD of 
5.6 (interquartile range [IQR], 3.1% to 7.2%) compared with 8.0% (IQR, 6.3% to 
9.3%) in control subjects. 
 Valdivielso P et al (68) analyzed endothelial function in systemic lupus 
erythematosus (SLE), and its relationship with disease activity and subclinical 
arteriosclerosis. They studied a group of 26 patients with SLE and 21 age- and sex-
matched controls. None of the patients or controls had had any ischemic event. Data 
were recorded on medical history, anthropometrics, prior treatment and the lupus 
activity index (LAI). Endothelial function was quantified by flow-mediated 
dilatation in the brachial artery. The presence of subclinical arteriosclerosis was 
assessed by the average intima-media thickness (IMT) on carotid ultrasound. The 
patients and the controls had a similar degree of carotid IMT (0.58+/-0.08 mm vs. 
0.57+/-0.07 mm, NS) and a similar prevalence of carotid plaque (27% vs. 24%, NS). 
However, the SLE patients had worse endothelial function than the controls (FMD 
12.4+/-4.4% vs. 16.9+/-5.5%, p<0.05). This difference remained after adjusting for 
age, smoking, body mass index, waist circumference, total cholesterol, triglycerides, 
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HDL cholesterol, apolipoproteins A-1 and B100 and postmenopausal status. A 
significant association was found in the SLE patients between FMD and LAI 
(Spearman Rho -0.462, p<0.05). SLE-associated endothelial dysfunction was 
present in patients who have no prior ischemic events and with the same degree of 
subclinical arteriosclerosis as controls. Moreover, the endothelial dysfunction was 
significantly associated with the degree of disease activity. There was difference 
among these studies with regard to the inclusion of disease duration, comorbities & 
use of immunosuppressants.  
 Piper M K et al (70) compared thirty-six female SLE patients with 22 
healthy age and sex matched controls. Endothelial dependent vasodilatation (EDD) 
was assessed at the brachial artery in response to shear stress. SLE patients showed 
significantly impaired endothelial function (median EDD 5.6%, IQR 3.1-7.2%) 
compared with healthy controls (median EDD 8.0%, IQR 6.3-9.3%; P = 0.001).  
 Zahra Seyyedbonakdar et al (69) evaluated the prevalence of vascular 
endothelial dysfunction and its risk factors in SLE women and then to identify its 
correlation with the disease activity, duration and concomitant conditions in these 
patients. Eighty four female SLE patients and 18 healthy young female were 
included in the study. The vascular endothelial function was evaluated via 
ultrasonographic assessment of the brachial artery diameter to determine flow 
mediated dilation (FMD). SLE patients had higher prevalence of impaired FMD 
than healthy subjects (48.8 vs. 5.5 %). But FMD impairment did not have any 
significant correlation with disease activity, duration, the presence of the anti-
dsDNA, anticardiolipin antibodies, antiphospholipid syndrome, hypertension, 
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hyperlipidemia, diabetes mellitus, hypothyroidism, history of lupus nephropathy, 
and history of receiving cyclophosphamide pulses. 
 Elizabeth Turner et al (71) measured flow-mediated dilation of the brachial 
artery using high resolution ultrasound and the presence or absence of coronary 
calcification by electron beam computed tomography. Twenty patients (17 female) 
median age (interquartile range) 42.5 (32.0–47.5) years were studied. The median 
flow-mediated vasodilatation was 3.6% (1.7%–7.7%). In patients with coronary 
calcification (n = 6), flow-mediated dilation was 2.1% (−0.42%–3.6%) compared 
with 4.0% (3.5%–8.3%) in those without (p = 0.12). There was no significant 
relationship between flow-mediated dilation and markers of disease activity, 
duration of disease, and cardiovascular risk factors. Lower flow-mediated dilation 
was associated with duration of corticosteroid therapy.  
 Lai-Shan Tam et al (72) examined whether acute hyperhomocysteinaemia 
exacerbates endothelial and platelet dysfunction in patients with SLE.  Twelve SLE 
patients and 15 controls were recruited. Oral methionine was used to achieve acute 
hyperhomocysteinaemia. Endothelial function was assessed by flow-mediated 
dilatation (FMD) of the brachial artery; also assessed were the levels of von 
Willebrand factor (vWF) and plasminogen activator inhibitor type 1 (PAI-1). 
Platelet activation was assessed by the levels of beta-thromboglobulin (beta-TG), 
fibrinogen binding, and P-selectin expression using flow cytometry. After oral 
methionine loading, vWF levels increased significantly, whereas FMD remained 
unchanged in both groups. PAI-1 increased significantly only in controls. Fibrinogen 
binding to platelets increased significantly only in SLE patients. Beta-TG remained 
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unchanged in SLE patients but increased significantly in controls. Platelet P-selectin 
expression did not change in either group. These results suggest that the 
prothrombotic tendency after acute hyperhomocysteinaemia is mediated by 
endothelial dysfunction and platelet activation in patients with SLE and healthy 
controls. 
 Parasar Ghosh et al (73) studied Asian Indians with SLE, to find out the 
prevalence and predictors of carotid intima-medial thickness (IMT) and brachial 
artery flow-mediated dilatation. Endothelial dysfunction was assessed by FMD in 
brachial artery and IMT was measured in common carotid artery in SLE patients and 
healthy controls. Sixty SLE patients (mean age 31±9 years) and 38 healthy controls 
(mean age 34±6 years) were included. The IMT was higher in SLE patients as 
compared to controls (0.49±0.08 mm vs. 0.39±0.05 mm, p<0.0001). SLE and 
damage were independent predictors of abnormal IMT. FMD was impaired in SLE 
patients compared to controls (9.97% vs. 18.97%, p<0.00001). None of the classical 
cardiovascular risk factors were predictors of FMD or abnormal IMT. Their study 
has shown a good negative correlation between brachial FMD and carotid IMT 
which have also been shown in other studies (74). 
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Guidelines for the ultrasound assessment of endothelial-dependent flow-
mediated vasodilation of the brachial artery (9). 
Mary C. Corretti, MD et al has led the report submitted by the International 
Brachial Artery Reactivity Task Force.  
Subject preparation:   
 Numerous factors affect flow-mediated vascular reactivity, including 
temperature, food, drugs and sympathetic stimuli, among others. Therefore, subjects 
should fast for at least 8 to 12 h before the study, and they should be studied in a 
quiet, temperature-controlled room. All vasoactive medications should be withheld 
for at least four half-lives, if possible. In addition, subjects should not exercise, 
should not ingest substances that might affect FMD such as caffeine, high-fat foods 
and vitamin C or use tobacco for at least 4 to 6 h before the study.  
Equipment:    
 Ultrasound systems must be equipped with vascular software for two-
dimensional (2D) imaging, color and spectral Doppler and a high-frequency vascular 
transducer. A linear array transducer with a minimum frequency of 7 MHz, attached 
to a high-quality mainframe ultrasound system, is used to acquire images with 
sufficient resolution for subsequent analysis. Image resolution is enhanced with 
broadband (multiple-frequency: 7 to 12 MHz) linear array transducers. 
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Image acquisition:    
 The subject is positioned supine with the arm in a comfortable position for 
imaging the brachial artery. The brachial artery is imaged above the antecubital 
fossa. A segment with clear anterior and posterior intimal interfaces between the 
lumen and vessel wall is selected for continuous 2D grayscale imaging. 
 Endothelium-dependent FMD: To create a flow stimulus in the brachial 
artery, a sphygmomanometric (blood pressure) cuff is first placed either above the 
antecubital fossa or on the forearm. A baseline rest image is acquired, and blood 
flow is estimated by time-averaging the pulsed Doppler velocity signal obtained 
from a midartery sample volume. Thereafter, arterial occlusion is created by cuff 
inflation to suprasystolic pressure. Typically, the cuff is inflated to at least 50 mm 
Hg above systolic pressure to occlude arterial inflow for a standardized length of 
time. This causes ischemia and consequent dilation of downstream resistance vessels 
via autoregulatory mechanisms. Subsequent cuff deflation induces a brief high-flow 
state through the brachial artery (reactive hyperemia) to accommodate the dilated 
resistance vessels. The resulting increase in shear stress causes the brachial artery to 
dilate. The image of the artery is recorded continuously from 30 s before to 2 min 
after cuff deflation. 
 Studies have variably used either upper arm or forearm cuff occlusion, and 
there is no consensus as to which technique provides more accurate or precise 
information. When the cuff is placed on the upper part of the arm, reactive 
hyperemia typically elicits a greater percent change in diameter compared with that 
produced by the placement of the cuff on the forearm (75, 76 & 77). This may be 
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due to a greater flow stimulus resulting from recruitment of more resistance vessels 
or possibly to direct effects of ischemia on the brachial artery. However, upper-arm 
occlusion is technically more challenging for accurate data acquisition as the image 
is distorted by collapse of the brachial artery and shift in soft tissue. The change in 
brachial artery diameter after cuff release increases as the duration of cuff inflation 
increases from 30 s to 5 min. The change in diameter is similar after 5 and 10 min of 
occlusion; therefore, the more easily tolerated 5-min occlusion is typically used. 
Also, FMD may be studied in the radial, axillary and superficial femoral arteries. 
Notable caveats are that arteries smaller than 2.5 mm in diameter are difficult to 
measure and vasodilation is generally less difficult to perceive in vessels larger than 
5.0 mm in diameter (78, 79 & 80). 
Anatomic landmarks:    
 The diameter of the brachial artery should be measured from cross sectional 
images in which the lumen-intima interface is visualized on the near (anterior) and 
far (posterior) walls. These boundaries are best visualized when the angle of 
insonation is perpendicular. Thus, clear visualization of both the near and far wall 
lumen-intima boundaries indicates that the imaging plane is bisecting the vessel and 
diameters measured from these images likely reflect the true diameter. Once the 
image for analysis is chosen, the boundaries for diameter measurements are 
identified manually with electronic calipers or automatically using edge-detection 
software. The variability of the diameter measurement is greatest when it is 
determined from a point-to-point measurement of a single frame, and least when 
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there is an average derived from multiple diameter measurements determined along 
a segment of the vessel.  
 The diameter measurement along a longitudinal segment of vessel is 
dependent upon the alignment of the image. Skew occurs when the artery is not 
completely bisected by the plane of the ultrasound beam. With slight skew, the 
maximal diameter measured is constant, and thus yields a more accurate 
measurement. Some edge-detection programs can account for skew from transducer 
angulation (79, 81).  
Timing of FMD:    
 Flow-mediated vasodilation is an endothelium-dependent process that 
reflects the relaxation of a conduit artery when exposed to increased shear stress. 
Increased flow, and thereby increased shear stress, through the brachial artery occurs 
during post occlusive reactive hyperemia. Several studies have suggested that the 
maximal increase in diameter occur approximately 60 s after release of the occlusive 
cuff, or 45 to 60 s after peak reactive hyperemic blood flow (80, 82). The increase in 
diameter at this time is prevented by the NOS inhibitor NG-monomethyl-L-arginine, 
indicating that it is an endothelium-dependent process mediated by NO (83, 84). 
Other measures of vasodilator response include time to maximum response (85), 
duration of the vasodilator response and the area under the dilation curve. 
Characterizing FMD:    
 Flow-mediated vasodilation is typically expressed as the change in post-
stimulus diameter as a percentage of the baseline diameter (86).  
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Evaluating precision of the technique:    
 Intraobserver and interobserver variability in image acquisition and analysis 
should be established and periodically reassessed for each condition, including 
baseline, reactive hyperemia and NTG administration. The highest reproducibility is 
likely to be shown over a short interval, during which the individual vasodilator 
response is unlikely to have changed owing to environmental or other influences. 
This can be accomplished by taking two measurements on the same day within a 10- 
to 15-min interval, or on separate days in otherwise identical circumstances. 
Longitudinal studies in which interventions over weeks to months are tested require 
that reproducibility measurements be performed at longer intervals. The image 
analysis and measurement of the vasodilator response from repeated studies should 
be performed by an individual who is blinded as to sequence. Measurement 
variability is assessed, typically, by a designated core laboratory for multicenter 
trials, prior to site certification and periodically thereafter to analyze for temporal 
drifts. Assessment of FMD of the brachial artery in clinical trials has increased 
because of its seeming ease of use, efficiency and noninvasive nature. Owing to the 
biological and technical variability of the measurement, several caveats should be 
considered when planning a clinical trial where FMD is the end point of interest. 
These include study design, sample size and uniform technique.  
Study design:  
 Recent studies have reported on the effect of pharmacologic or physiologic 
interventions on FMD of the brachial artery. These include both acute (87, 88, 89) 
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and longer-term intervention trials (90, 91&92). Both parallel-group and crossover 
designs have been successfully employed.  
Sample size.    
 Typically, significant improvement in FMD can be seen with 20 to 30 
patients in a crossover design study and 40 to 60 patients in a parallel-group design 
study. In studies of this size, the minimal statistically significant improvement that 
can be detected with intervention is an absolute change in FMD of 1.5% to 2%. The 
sample size depends greatly on the variance of repeated measurement in the control 
group in a particular vascular laboratory. 
 With intervention trials, an important parameter to report is the time-
dependent reproducibility of FMD. For example, in the placebo group, the 
pretreatment and post intervention FMD measures are usually reported, and often 
are very similar. However, if the mean difference between the two measurements for 
each patient is quite high, it indicates that the variance of the technique might limit 
interpretation of the study results. An acceptable reproducibility is a mean difference 
of 2% to 3% in FMD over time (on a baseline vasodilation of about 10%) (93). This 
value has not been readily available in published trials.  
Methodology:    
 As discussed above, several techniques have been employed to measure 
FMD (94, 95). Laboratories should select the method that gives them the most 
reproducible results, and for multicenter studies, the same scanning protocol should 
be employed at all sites. For studies employing repeated measurements following 
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intervention, FMD might change as a result of the intervention. However, FMD 
could also be affected by a change in the hyperemic stimulus. Therefore, the flow 
stimulus should be consistent. Otherwise, any change in FMD of the conduit artery 
may be related to changes in flow (indirectly mediated by changes in the 
microcirculation) rather than improvement of endothelial function of the conduit 
vessel per se.  
 Ultrasound assessment of brachial artery FMD has yielded important 
information about vascular function in health and disease, yet several new 
approaches and technological advances have emerged. Most prior studies examined 
FMD at a single time point, typically 1 min after cuff release. This practice evolved 
from the observations that the maximal dilator response occurs at approximately 1 
min in healthy subjects (96) and that the necessity for manual acquisition and 
measurement placed a practical limit on the number of image frames that could be 
analyzed.  
 Commercially available technology now makes it possible to acquire 
multiple images of the brachial artery automatically using the ECG signal as a 
trigger and to measure arterial diameter automatically using computer-based edge-
detection techniques. This approach allows investigators to examine the entire time 
course of brachial dilation in response to reactive hyperemia, the true peak response, 
the time to peak and the overall duration of FMD as discussed in the previous text. 
The time course and extent of brachial expansion within a single cardiac cycle, 
possibly reflecting vessel compliance, can be examined. In the carotid artery, 
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compliance has been shown to correlate with cardiovascular risk (97). About 70% of 
the dilation observed 1 min after cuff release is attributable to NO synthesis (98, 99).  
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AIM OF THE STUDY 
1)   To evaluate endothelial function and to assess the extent of dysfunction in 
newly diagnosed SLE patients by using the measures of flow mediated 
dilatation of the brachial artery and carotid intima media thickness. 
2)  To study the correlation of flow mediated dilatation with carotid intima 
medial thickness.  
3)  To study the relationship between endothelial dysfunction and clinical 
characteristics of SLE. 
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MATERIALS AND METHODS 
Inclusion Criteria: 
1) Newly diagnosed SLE patients by ACR criteria of age 16 yrs and above. 
Exclusion Criteria: 
1) Patients with co morbidities like hypertension, diabetes mellitus and 
hyperlipidemia.  
2) Patients with history of cardiovascular disease (angina, myocardial infarction, 
congestive cardiac failure).     
3) Patients with renal failure (creatinine >3 mg/dl or creatinine clearance <30 
ml/min). 
4) Patients who were on long term medications like prednisolone, other 
immunosuppressants & statins prior to our evaluation. 
5) Patients with clinical evidence of upper limb vascular insufficiency in the form 
of pre gangrene or gangrene. 
6) Patients with overlap syndrome. 
7) Infections in the previous four weeks. 
8) Pregnancy or lactation in the previous 6 weeks. 
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Subjects: 
 Patients were recruited from the rheumatology outpatient clinic and wards of 
Government General Hospital, Chennai, during the period February 2009- February 
2010.   Fifty eligible patients older than 16 years of age were enrolled. They fulfilled 
at least four classification criteria for systemic lupus erythematosus by 1997 ACR 
revised criteria, with no known preexisting cardiovascular disease; and were willing 
to undergo measurement of flow-mediated dilation. 
 Healthy control subjects were recruited from the clinically normal secretarial 
and support staff as well as from friends of patients. All subjects gave written 
informed consent to take part in this study, which was approved by the ethical 
committee.  
Clinical and Laboratory Assessment: 
 All subjects had a detailed history and examination to look for traditional 
cardiovascular disease risk factors, vasculitis, Raynaud’s phenomenon, and 
secondary antiphospholipid syndrome. In patients, disease activity and cumulative 
damage were assessed by the SLE Disease Activity Index (SLEDAI) and the 
Systemic Lupus International Collaborating Clinics (SLICC) respectively. 
Laboratory evaluations include complete blood count, ESR (Westergren’s method), 
liver function test, renal function test, fasting blood sugar and lipid profile. 
Immunological assay were CRP (Latex agglutination method); ANA (CalBiotech 
Inc ANA Screen ELISA kit); Anti dsDNA (Wampole laboratories dsDNA ELISA 
test); Anti cardiolipin antibody (CalBiotech cardiolipin IgG & IgM ELISA kit) & 
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C3, C4 complement levels (Nephelometry). The lupus anticoagulant study was done 
with the dilute Russell viper venom test & activated partial thromboplastin time; 
were also assayed.  
ELISA results were interpreted as follows: 
ANA 
< 0.9 – Negative. 
0.9- 1.1 - Borderline positive. 
> 1.1 - Positive. 
 
Anti dsDNA 
< 0.9 - Negative 
0.91 – 1.09 – Equivocal 
> 1.1 – Positive. 
ACL IgG  
< 10 GPL– Negative 
10- 15GPL – Borderline positive. 
15- 80 GPL– Moderate positive. 
>80 GPL– High positive.  
ACL IgM 
< 15 MPL – Negative 
15- 20 – Borderline positive 
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21- 80 – Moderate positive 
> 80 – High positive. 
Complement Assay (Nephelometry) 
Normal range: 
C3 - 88 – 201 mg/dl. 
C4 – 16 – 47 mg/dl. 
 All patients had Electrocardiogram, chest X ray, ultrasound abdomen and an 
Echocardiogram done by a cardiologist. 
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Assessment of Endothelial Function: 
 Endothelial function was assessed with high-resolution B-mode Doppler 
(Siemens Alterces with a 7.5 MHz linear-array transducer Photo (A))   examination 
of the brachial artery using the protocol described as in the guidelines cited above 
(9). We measured flow-mediated dilation (FMD) in response to reactive hyperemia. 
All subjects were studied between 8 and 11 AM after a12-hour overnight fast. They 
were asked not to smoke on the morning of study and to avoid alcohol for 48 hours. 
The brachial artery was scanned 10 cm above the antecubital fossa (Photo B). 
Distance measured was from anterior to posterior M lines (media-adventitia 
interface), and every measurement was taken by sonologist blinded to cases and 
controls. Then, ischemia was induced by inflating the pneumatic cuff to a pressure 
50 mmHg above systolic one, in order to obliterate the brachial artery. After 5 
minutes, the cuff was deflated and the diameter was measured after 60 seconds post-
deflation (Df).  
 FMD is calculated as follows: 100 %x [(post deflation diameter–resting 
diameter)/resting diameter]. To assess reproducibility of our technique, we looked at 
the reliability of reading scans on 2 separate occasions by a single blinded observer. 
For this, 15 scans from patients or control subjects were chosen at random. The 
intraclass correlation coefficients for resting diameter and FMD were 0.93 (95% CI, 
0.56 to 0.95) and 0.82 (95% CI, 0.30 to 0.97), respectively.  
 
 
                                                      
 
45
A)    
 
        
 
 
 
 
(B)  
                                                                           
 
 
 
 
 
 
                                                      
 
46
Carotid Artery Intima -Media Thickness and Plaque:  
 Patients and control subjects also had the intima-media thickness (IMT) of 
their carotid artery measured using high-resolution B-mode Doppler (Siemens 
Alterces with a 3-15 MHz linear-array transducer). The common carotid artery was 
scanned longitudinally, and the IMT measurement was taken in the proximal part of 
the common carotid artery, 1 cm proximal to the carotid bulb as the maximum 
distance between the intima-lumen and adventitia-media interfaces in areas without 
carotid plaque (100). IMT was determined as the average of 6 measurements, 3 each 
from the left and right common carotid arteries. This is shown in the Photo E. 
 We also noted the presence or absence of carotid plaques, with plaque being 
defined using the criteria described by Li et al (101). The intraclass correlation 
coefficient for IMT measurements, assessed in 15 subjects on 2 separate occasions 2 
weeks apart, was 0.92 (95% CI, 0.84 to 1.00).  
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Statistical Analysis 
 The statistical analysis was performed using the SPSS (version 17.0).  
Results are presented as mean ± SD, except for frequencies, which are 
expressed as percentages.  
Unpaired student’s t- test has been used for comparing the FMD, carotid 
IMT and other features of the study and control group. 
 p < 0.05 was considered statistically significant.     
Pearson’s test has been used for studying the correlation between flow 
mediated dilatation and variables.  
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RESULTS 
 The demographic, clinical and investigation features of the studied groups 
were as follows: 
                                  TABLE 1:  Characteristics of the group 
Parameter Patient (n=50) Control (n=50) P value 
Male/Females 3/47 3/47 1.00 
Mean Age (yrs) 23 ± 5.41 23  ± 5.41 1.00 
BMI (kg/m2) 19.6 ± 1.77 20 ±  1.71 0.31 
Mean duration of  
symptoms (months) 
7.3 0 - 
Systolic BP (mmHg) 112 ± 8.03 111 ±  7.7 0.59 
Diastolic BP (mmHg) 79.6 ±  5.83 79.2 ±  5.52 0.75 
Total Cholesterol 
(mg/dl) 
169 ± 23.4 175 ± 19.7 0.13 
Triglycerides (mg/dl) 114 ± 11.9 113 ± 10.2 0.56 
HDL (mg/dl) 43.6 ±  3.5 42.9 ±  2.51 0.20 
LDL (mg/dl) 108 ± 10.3 105 ± 8.61 0.09 
 
 There were 47 females and 3 males, who were age and sex adjusted in the 
patient and control group. The mean duration of disease according to the onset of 
symptoms, was 7.3 months with a minimum duration of one month to a maximum of 
14 months. There was no statistically significant difference with regard to the blood 
pressure and fasting lipid profile between both the groups.  
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Clinical characteristics of the SLE patients: 
 The patient group had the following clinical features in the proportion given: 
mucocutaneous – 88% (n=44); constitutional – 86% (n=43); musculoskeletal – 41% 
(n=82%); serositis – 22% (n=11); hematological – 6% (n=12%); neuropsychiatric – 
8% (n=4); renal – 2% (n=1); Raynaud’s – 0. The mean SLEDAI score was 11.6.The 
median SLEDAI score was 11 (range, 3 to 29). The median SLICC was 0 (range 0 
to 1). Since we had chosen patients at diagnosis, and by excluding the patients who 
had been on immunosuppressants prior to our evaluation, we had a relatively naïve 
population who had not been on specific disease modifying drugs.  
 On evaluation, the patient population had the following immunological 
features. 
             TABLE 2: Immunological profile the patient group was as follows: 
Parameter Patient group (n=50) 
ANA 100% (n=50) 
Anti dsDNA 78% (n=39) 
Low C3/C4 assay 36% (n=18) 
ACL IgG/IgM  16% (n=8) 
LAC 10% (n=5) 
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TABLE 3: Study characteristics in the patient and control group 
Parameter Patient group Control group p value 
Baseline Diameter 
(mm) 
3.64± 0.40 3.67 ± 0.34 0.64 
FMD (%) 12 ± 3.92 19.8 ± 2.27 < 0.001 
Carotid IMT (mm) 0.38 0.36 0.09 
 
 The patients and the controls had a similar degree of baseline diameter of the 
brachial artery (3.64 ± 0.40 vs. 3.67 ± 0.34 mm, p = 0.64) and carotid IMT (0.38 ± 
0.08 vs. 0.36   ± 0.06, p value 0.09). However, the SLE patients had worse 
endothelial function than the controls (FMD 12 ± 3.92% vs. 19.8 ± 2.27%, p<0.001). 
The endothelial function, assessed by vascular ultrasonography on brachial artery, is 
shown (Baseline Photo (C) & post dilatation Photo (D). The carotid IMT 
measurement is shown in Photo (E). 
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Correlations between FMD and SLE parameters: 
 The correlations between FMD and biological and immunological 
parameters are shown in Table 4. 
TABLE 4: Parameter Correlation coefficient 
Disease duration                                     r = 0.0998                             p = 0.49 
Carotid IMT                                           r = – 0.1993                          p = 0.16 
SLEDAI                                                   r = – 0.5678                          p = <0.01    
C3                                                             r =    0.9101                          p = < 0.01     
Anti dsDNA antibodies                          r =  – 0.8658                         p = <0.01      
Total cholesterol                                     r =  0.0239                            p = 0.86       
ACL IgG                                                 r =  0.2388                             p = 0.09        
ACL IgM                                                 r =  0.2149                            p = 0.13        
 
 The statistical analysis showed an inverse correlation between FMD and 
antidsDNA and SLEDAI which is significant statistically. Similarly there is strong 
positive correlation between FMD and C3.  But, correlation does not imply 
causation.                        
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The size of any correlation generally evaluates as follows: 
Value of r Qualitative Description of the 
Strength 
–1 perfect negative  
(–1, –0.75) strong negative  
(–0.75, –0.5) moderate negative  
(–0.5, –0.25) weak negative  
(–0.25, 0.25) no linear association  
(0.25, 0.5) weak positive  
(0.5, 0.75) moderate positive  
(0.75, 1) strong positive  
1 perfect positive  
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DISCUSSION 
 The patients with SLE have a high incidence of atherosclerosis with its main 
consequence: coronary artery disease. Epidemiological studies have shown that SLE 
women aged 35 – 44 years were over 50 times more likely to develop myocardial 
infarction than women of similar age from general population (3). Anatomo-
pathological investigations have revealed that the SLE patients were prone to 
develop a premature atherosclerosis (102). The increased risk of atherosclerosis is 
not exclusively related to traditional risk factors alone (103). In the last years, SLE 
itself appeared like an independent risk factor for atherosclerosis, acting through 
autoimmune vascular injury (6). In patients with systemic lupus erythematosus, 
atherosclerosis has a long period of subclinical evolution. The first reversible step in 
the atherogenesis process is represented by the endothelial dysfunction (104).  
 Endothelial dysfunction is well described entity in connective tissue diseases, 
leading to accelerated atherosclerosis and associated morbidity and early mortality. 
There are several associated factors like body mass index, co morbidities, 
immunosuppressants, dyslipidemia, hypertension which could contribute to the 
endothelial dysfunction. Our study was designed to first identify the prevalence of 
this in our patients and more importantly attempt to delineate the disease 
contribution from all associated factors. In this regard, we have chosen newly 
diagnosed cases who have not been on treatment and have excluded other associated 
factors like hypertension, dyslipidemia & diabetes mellitus. We could thereby to an 
extent, isolate the disease related factor and attribute the endothelial dysfunction to 
it. 
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 Endothelial dysfunction appears when the normal functions of the 
endothelial cells (control of vascular tone and blood pressure, regulation of 
leucocytes traffic from the blood to the tissues, and platelet adhesion and 
aggregation, maintenance of the balance between blood coagulation and fibrinolysis, 
control of growth, development and differentiation of the vessel wall cells) are lost 
or dysregulated (105). A non-invasive method for the assessment of endothelial 
dysfunction is represented by flow mediated vasodilation (endothelium dependent 
dilation) (106). In our study, FMD in SLE patients was significantly lower than in 
control subjects (FMD 12±3.92% vs. 19.8±2.27%, p<0.001). There are several 
studies with similar results, starting with the first study, performed by Lima et al. 
(107), who showed that SLE patients presented lower FMD than sex and age-
matched controls (5.0±5.0% vs. 12.0± 6.0%) , even in subjects without traditional 
cardiovascular risk factors (70). Tani et al. (16) identified the same pattern of FMD 
in SLE patients as well as by Valdivielso et al (68) (FMD 12.4+/-4.4% vs. 16.9+/-
5.5%, p<0.05). The reduced values of FMD in patients with SLE were found by 
Piper and Turner in their studies, too (67, 71). Our study concurred with the FMD 
results of the other indian study done by Parasar Ghosh et al (73) which was 
impaired in SLE patients compared to controls (9.97% vs. 18.97%, p < 0.00001).  
 The Carotid IMT values showed no significant difference in our study and 
control population (0.38 ± 0.08 vs. 0.36   ± 0.06, p value 0.09). Similar results were 
obtained in the study done by Valdivielso et al (68) (0.58+/-0.08 mm vs. 0.57+/-
0.07 mm, NS).  Parasar Ghosh et al (73) have reported higher carotid IMT in SLE 
patients as compared to controls (0.49 ± 0.08 mm vs. 0.39 ± 0.05 mm, p < 0.0001) and 
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had shown a good negative correlation between brachial FMD and carotid IMT, 
which was not the case in our study. Masoud El-Magadmi et al (67) & Zahra 
Seyyedbonakdar et al (69) also observed a negative correlation with percent FMD 
in their studies. The reason for this difference could be that in early stages of the 
disease to which our patients belonged to, identification of a functional abnormality 
(FMD) would have preceded the structural changes that occur in the carotid arteries 
in the form of intima medial thickness that occurs on a later stage. Moreover the 
other factors which would contribute to subclinical atherosclerosis like comorbities, 
immunosuppressants were not excluded in their studies as against ours. 
 We found a moderate negative correlation between FMD and SLEDAI (r = – 
0.7321, p < 0.001). This correlation between FMD and the disease activity was 
identified in other studies (96, 108 & 109). Valdivielso et al (68) also have reported 
significant correlation between FMD and LAI (Lupus Activity Index). AntidsDNA 
had a strong negative correlation, while C3 complement assay had strong positive 
correlation with flow mediated dilatation. There was no linear correlation between 
other factors like disease duration, cholesterol, anticardiolipin antibodies.  
 When comparing our study with the other indian study done by Parasar 
Ghosh et al (73) regarding other factors, our study population has less disease 
duration ( mean 7.3 months) when compared to their patient population ( mean 60 
months). Similarly their patient population had co morbidities (hypertension, 
diabetes mellitus, dyslipidemia), and had been exposed to several 
immunosuppressants. These factors have their contribution in the endothelial 
dysfunction.   
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 FMD using vascular ultrasonography on brachial artery represents a useful, 
non-invasive method for the assessment of the endothelial dysfunction. Reactive 
hyperemia produces a shear stress stimulus that induces the normal endothelium to 
release nitric oxide (NO), which acts as a vasodilator. Impaired endothelial function 
is associated with a reduced release of NO and a lower vasodilation (110). The effect 
of disease states and/or interventions on the blood flow response to cuff occlusion 
(reactive hyperemia) is under explored. Current technology limits the utility of 
spectral Doppler to reproducibly assess changes in flow, which might provide useful 
information about endothelial function of the microvasculature.  
 Ongoing studies in several large populations, including the Framingham 
Heart Study and the Cardiovascular Health Study, shall determine whether 
endothelial dysfunction in the brachial artery will identify patients at risk for 
developing coronary artery disease, cerebral vascular disease and/or peripheral 
vascular disease. The technique is particularly well suited for study of the earliest 
stages of atherosclerosis in children and young adults, thus providing maximal 
opportunity for prevention.  
 Numerous studies have demonstrated that brachial artery reactivity improves 
with risk factor modification and treatment with drugs known to reduce 
cardiovascular risk. It remains unknown whether an improvement in endothelial 
function directly translates into improved outcome. In the future, however, 
practitioners may use brachial artery FMD to assess response to drug therapy and to 
individualize patient risk factor modification programs. Further studies are needed to 
determine whether the methodology is sufficiently reproducible and whether 
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biological variability is sufficiently low to make assessment of FMD a clinically 
useful measure of cardiovascular risk on an individual or group basis. To that end, 
the methodology will need to mature, with formal opportunities for training, 
certification and continuing medical education, as currently exist for other 
cardiovascular testing modalities.  
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FUTURE DIRECTIONS 
 Ultrasound assessment of brachial artery FMD has yielded important 
information about vascular function in health and disease, yet several new 
approaches and technological advances have emerged. Most prior studies examined 
FMD at a single time point, typically 1 min after cuff release. This practice evolved 
from the observations that the maximal dilator response occurs at approximately 1 
min in healthy subjects (111) and that the necessity for manual acquisition and 
measurement placed a practical limit on the number of image frames that could be 
analyzed. Commercially available technology now makes it possible to acquire 
multiple images of the brachial artery automatically using the ECG signal as a 
trigger and to measure arterial diameter automatically using computer-based edge 
detection techniques. This approach allows investigators to examine the entire time 
course of brachial dilation in response to reactive hyperemia , the true peak 
response, the time to peak and the overall duration of FMD as discussed in the 
previous text. The time course and extent of brachial expansion within a single 
cardiac cycle, possibly reflecting vessel compliance, can be examined. In the carotid 
artery, compliance has been shown to correlate with cardio- vascular risk (112). 
About 70% of the dilation observed 1 min after cuff release is attributable to NO 
synthesis. 
 Further studies are needed to evaluate other vasoactive mechanisms and to 
determine whether various disease states influence the kinetics and/or extent of 
FMD. Careful examination of the vasodilator response to NTG provides another 
potential avenue for investigation. Although most studies have detected little effect 
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of disease states on this response, there is evidence that cardiovascular risk factors 
might impair the vasodilator response to NTG, especially when a dose-response 
curve is measured. These findings are consistent with experimental studies 
demonstrating that inactivation of NO by reactive oxygen species is an important 
mechanism of vascular dysfunction. Further information about the causes of 
vascular dysfunction and the response to interventions may be gained by examining 
the response to a sub maximal dose of NTG or a series of NTG doses. The effect of 
disease states and/or interventions on the blood flow response to cuff occlusion 
(reactive hyperemia) is under explored. Current technology limits the utility of 
spectral Doppler to reproducibly assess changes in flow, which might provide useful 
information about endothelial function of the microvasculature. 
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CONCLUSION 
1) Endothelial dysfunction is present in SLE patients even in the absence of 
traditional cardiovascular risk factors. 
2) FMD using vascular ultrasonography on brachial artery represents a non-
invasive, reproducible and cost effective tool for the assessment of 
endothelial dysfunction. 
3) Impaired flow mediated dilatation of brachial artery may be an early 
physiological feature of endothelial dysfunction and may precede the 
anatomical increase in carotid intimal thickness.  
4) FMD of brachial artery has significant negative correlation with disease 
activity and antidsDNA antibody. 
5) Future prospects of FMD technique include  
a) early screening module for endothelial dysfunction and to start on drugs 
with  pleotrophic effect like statins, ACE inhibitors and Aspirin. 
 b) serial screening method to ascertain improvement while on treatment with       
immunosuppressive agents and vasodilators.   
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ABBREVIATIONS 
 SLE                    Systemic lupus erythematosus 
 FMD                      Flow-mediated vasodilatation 
 CVD                      Cardiovascular disease 
 IMT                       Intima-media thickness  
 LAI                        Lupus activity index 
 EDD                      Endothelial dependent vasodilatation  
 BMI                       Body mass index 
 SLEDAI                SLE Disease Activity Index   
 SLICC                   Systemic Lupus International Collaborating Clinics  
 ESR                       Erythrocyte sedimentation rate 
 CRP                       C Reactive protein 
 ANA                      Anti nuclear antibody 
 Anti dsDNA        Anti double stranded DNA 
 aCL                       Anticardiolipin antibody  
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PROFORMA 
 
NAME:                                    AGE/SEX:                                 OP/ IP No:                           
 
RCC No    : 
 
ADDRESS:                                                                        OCCUPATION: 
 
 
H/O PRESENT ILLNESS:                           TOTAL DURATION OF ILLNESS  
             
Fever                                  Malaise                                    Fatigue   
                                                      
Malar rash                          Discoid lesion                       Oral ulcer                            
 
Alopecia                             Photosensitivity   
 
Purpura                              Raynaud’s                               Gangrene    
 
Joint Symptoms                          
 
Myalgia                              Weakness                                 Headache                                 
 
Visual sym                         Mood                                     Seizures      
                                                                                                
Chest pain                          Palpitation                               Dyspnoea 
 
Syncope                              Pedal edema  
Cough                                 Expectoration                          Hemoptysis                              
 
Hematuria                           Oliguria                             Facial puffiness                                            
 
OTHERS 
 
PAST HISTORY:    
                                                                         
PERSONAL HISTORY:    
                                           
TREATMENT HISTORY: 
 
PHYSICAL EXAMINATION: 
 
Fever                Anaemia        clubbing         cyanosis      LN       PE      JVP          
 
MUCOCUTANEOUS  
 
OTHERS 
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PULSE                                          BP                                             RR 
CVS                                                     RS                                                  ABDOMEN 
 
 
 
CNS                                              Fundus:                                          MSS: 
 
 
 
 
INVESTIGATIONS: 
 
Hb                   TC                   DC                          ESR 1 hr               Platelets                  
BT                   CT                   PT                INR    APTT 
Urea            Cr             Uric acid       Sugar              T.Bilirubin                   
ALT               AST 
SAP                LDH               CPK                    Na    K     HCO 3      Cl 
Lipid profile 
Urine R/E                                                          PCR                               24 hrs protein 
ANA                                                                 Anti dsDNA                   ACL 
LAC                                                               VDRL                           CRP  
Complement                                                   ENA 
 
Renal Biopsy : 
 
ECG                                                                                         CXR PA View 
ECHO                                                                                       Carotid IMT  
 
 
Flow Mediated Dilatation                   Baseline                          FMD                       
 
ASSESSMENT            SLEDAI                                                 SLICC 
 
 
MANAGEMENT 
 
NSAIDS                                                STEROIDS                Pulse                             
Oral 
IMMUNOSUPPRESSANTS                                                    
ANTICOAGULANTS/ANTIPLATELETS        
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SLEDAI 
Systemic Lupus Erythematosus Disease Activity Index 
Descriptor Definition Weighted 
Score 
Seizure Recent onset; exclude metabolic, infectious, or 
drug-related causes 
8 
Psychosis Altered ability to function in normal activity owing 
to severe disturbance in the perception of reality; 
includes hallucinations, incoherence marked by 
loose associations, impoverished thought content, 
marked illogical thinking, and bizarre disorganized 
or catatonic behavior; exclude the presence of 
uremia and offending drugs 
8 
Organic brain 
syndrome 
Altered mental function with impaired orientation 
or impaired memory or other intellectual function, 
with rapid onset and fluctuating clinical features; 
includes clouding of consciousness with reduced 
capacity to focus and inability to sustain attention 
on environment, and at least two of the following—
perceptual disturbance, incoherent speech, 
insomnia or daytime drowsiness, and increased or 
decreased psychomotor activity; exclude metabolic 
infectious and drug-related causes 
8 
Visual Retinal changes from systemic lupus erythematosus 
cytoid bodies, retinal hemorrhages, serous exudate 
or hemorrhage in choroid, optic neuritis (not due to 
hypertension, drugs, or infection) 
8 
Cranial nerve New onset of sensory or motor neuropathy 
involving a cranial nerve 
8 
Lupus headache Severe, persistent headache; may be migrainous, 
unresponsive to narcotic analgesia 
8 
Cerebrovascular 
accident 
New syndrome; exclude arteriosclerosis 8 
Vasculitis Ulceration, gangrene, tender finger nodules, 
periungual infarction, splinter hemorrhages; 
vasculitis confirmed by biopsy or angiogram 
8 
Arthritis More than two joints with pain and signs of 
inflammation (tenderness, swelling, or effusions) 
4 
                                                      
 
88
Descriptor Definition Weighted 
Score 
Myositis Proximal muscle aching or weakness associated 
with elevated creatine phosphokinase/aldolase 
levels, electromyographic changes, or biopsy 
specimen showing myositis 
4 
Casts Heme, granular, or erythrocyte 4 
Hematuria >5 erythrocytes per high-power field; exclude other 
causes (stone, infection) 
4 
Proteinuria >0.5 g of urinary protein excreted per 24 hr; new 
onset or recent increase of >0.5 g/24 hr 
4 
Pyuria >5 leukocytes per high-power field; exclude 
infection 
4 
New malar rash New onset or recurrence of inflammatory type of 
rash 
4 
Alopecia New or recurrent; patch of abnormal, diffuse hair 
loss 
4 
Mucous 
membrane 
New onset or recurrence of oral or nasal ulceration 4 
Pleurisy Pleuritic chest pain with pleural rub or effusion, or 
pleural thickening 
4 
Pericarditis Pericardial pain with at least one rub or effusion; 
confirmation by ECG or echocardiography 
4 
Low 
complement 
Decrease in CH50, C3, or C4 levels (to less than 
the lower limit of the laboratory-determined normal 
range) 
2 
Increased DNA 
binding 
>25% binding by Farr assay (to more than the 
upper limit of the laboratory-determined normal 
range, e.g., 25%) 
2 
Fever >38°C after exclusion of infection 1 
Thrombocytope
nia 
<100,000 platelets 1 
Leukopenia Leukocyte count <3000/mm3 (not due to drugs) 1 
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SLICC 
Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index for Systemic Lupus Erythematosus 
 
 
Item Score 
Ocular (either eye by clinical assessment)   
Any cataract ever 0, 1 
Retinal change or optic atrophy 0, 1 
Neuropsychiatric   
Cognitive impairment (e.g., memory deficit, difficulty with 
calculation, poor concentration, difficulty in spoken or written 
language, impaired performance level) or major psychosis 
0, 1 
Seizures requiring therapy for 6 mo 0, 1 
Cerebrovascular accident ever (score 2 if >1) 0, 1, 2 
Cranial or peripheral neuropathy (excluding optic) 0, 1 
Transverse myelitis 0, 1 
Renal   
Estimated or measured glomerular filtration rate <50% 0, 1 
Proteinuria >3.5 g/24 hr 0, 1 
or End-stage renal disease (regardless of dialysis or transplantation) or 3 
Pulmonary   
Pulmonary hypertension (right ventricular prominence, or loud P2) 0, 1 
Pulmonary fibrosis (physical and radiographic) 0, 1 
Shrinking lung (radiograph) 0, 1 
Pleural fibrosis (radiograph) 0, 1 
Pulmonary infarction (radiograph) 0, 1 
Cardiovascular   
Angina or coronary artery bypass 0, 1 
Myocardial infarction ever (score 2 if >1) 0, 1, 2 
Cardiomyopathy (ventricular dysfunction) 0, 1 
Valvular disease (diastolic murmur, or systolic murmur >3/6) 0, 1 
Pericarditis for 6 mo or pericardiectomy 0, 1 
Peripheral vascular   
Claudication for 6 mo 0, 1 
Minor tissue loss (pulp space) 0, 1 
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Significant tissue loss ever (e.g., loss of digit or limb) (score 2 if >1 
site) 
0, 1, 2 
Venous thrombosis with swelling, ulceration, or venous stasis 0, 1 
Gastrointestinal   
Infarction or resection of bowel below duodenum, spleen, liver or 
gallbladder ever, for any cause (score 2 if >1 site) 
0, 1, 2 
Mesenteric insufficiency 0, 1 
Chronic peritonitis 0, 1 
Stricture or upper gastrointestinal tract surgery ever 0, 1 
Chronic pancreatitis 0, 1 
Musculoskeletal   
Muscle atrophy or weakness 0, 1 
Deforming or erosive arthritis (including reversible deformities, 
excluding avascular necrosis) 
0, 1 
Osteoporosis with fracture or vertebral collapse (excluding avascular 
necrosis) 
0, 1 
Avascular necrosis (score 2 if >1) 0, 1, 2 
Osteomyelitis 0, 1 
Tendon rupture 0, 1 
Skin   
Scarring chronic alopecia 0, 1 
Extensive scarring of panniculus other than sculp and pulp space 0, 1 
Skin ulceration (excluding thrombosis for >6 mo) 0, 1 
Premature gonadal failure 0, 1 
Diabetes (regardless of treatment) 0, 1 
Malignancy (exclude dysplasia) (score 2 if >1 site)  
 
 
 
 
 
 
 
 
                                                      
 
91
CONSENT FORM 
                                                      
 
92
ETHICAL COMMITTEE APPROVAL 
 
 
 
 
 
 S.No RCC Age Sex Duration (mths) 
FMD IMT chol 
TGL HDL LDL anti dsDNA % mm mg 
1 52067 20 F 12 12.2 0.4 187 70 42 80 1.28 
2 49464 28 F 6 12.5 0.5 180 130 42 106 1.48 
3 50636 17 F 6 8.3 0.4 167 111 40 88 4.43 
4 51204 17 F 12 12.1 0.4 146 88 46 90 1.38 
5 51109 30 F 12 10.5 0.3 166 112 46 96 2.42 
6 49417 16 F 8 17.8 0.3 171 130 40 102 0.49 
7 51244 35 F 10 11.4 0.4 160 106 40 113 1.64 
8 51270 32 F 8 14.7 0.5 185 110 42 120 0.54 
9 49585 19 F 12 16.1 0.3 196 110 40 120 0.57 
10 51105 17 F 5 24.2 0.3 197 123 51 113 0.37 
11 51238 23 F 3 8.6 0.3 196 108 42 102 2.5 
12 51242 22 F 7 18.1 0.3 166 128 43 113 0.46 
13 51223 24 M 4 15.2 0.4 161 124 43 128 0.63 
14 51188 17 M 8 12.1 0.4 176 130 42 110 1.38 
15 51304 28 F 12 12.2 0.5 140 115 40 115 0.36 
16 49905 27 F 12 17.1 0.4 180 124 50 110 1.48 
17 51242 35 F 6 18.4 0.4 146 127 41 102 1.59 
18 51336 25 F 14 16.2 0.3 137 108 42 118 0.56 
19 51305 29 F 12 9.8 0.4 191 113 49 120 2.78 
20 51246 23 F 3 13.5 0.3 138 107 42 90 0.3 
21 50785 23 F 14 16.2 0.3 110 105 41 120 0.54 
22 49589 31 F 5  12.8 0.4 174 126 45 102 1.51 
23 51214 27 F 2 12.2 0.4 187 127 56 112 1.42 
24 51200 25 F 12 12.5 0.3 170 122 43 102 1.54 
25 51360 34 F 6 7.5 0.3 146 100 46 102 3.37 
26 50955 17 F 6 16.2 0.4 146 110 40 122 0.42 
S.No RCC Age Sex Duration (mths) 
FMD IMT chol 
TGL HDL LDL anti dsDNA % mm mg 
27 51703 20 F 3 16.1 0.5 189 133 40 114 0.49 
28 51125 21 F 6 7.5 0.6 192 112 42 112 3.98 
29 50344 20 F 10 4.9 0.5 124 108 42 86 5.14 
30 51388 23 F 5 4.9 0.4 194 130 46 112 4.94 
31 51449 21 F 12 7.5 0.4 140 110 42 96 3.98 
32 51399 17 F 4 7.9 0.3 146 110 47 112 3.45 
33 51445 20 F 6 7.5 0.3 192 106 44 122 3.06 
34 51472 19 F 5 6.5 0.3 132 124 52 112 4.2 
35 51531 18 F 4 7.9 0.4 198 122 42 110 3.89 
36 51648 21 F 12 12.1 0.3 188 113 47 102 1.59 
37 51622 21 F 6 13.3 0.4 182 113 41 102 1.38 
38 50098 18 F 12 10.8 0.4 194 93 47 113 2.56 
39 49510 16 F 6 8.8 0.4 192 120 42 102 3.05 
40 51762 25 F 12 8.6 0.4 172 113 42 102 3.26 
41 51851 27 F 3 11.8 0.3 177 124 44 114 2.32 
42 51831 27 F 6 14.2 0.4 169 114 46 110 0.8 
43 51891 28 F 1 8.6 0.6 170 113 42 102 3.42 
44 51911 18 F 12 13.3 0.3 195 125 40 122 1.28 
45 51630 25 F 3 12.9 0.4 118 108 46 108 1.18 
46 51977 20 F 3 12.9 0.4 188 108 45 112 1.3 
47 51278 29 F 3 15.2 0.5 188 102 42 106 0.8 
48 51983 19 F 4 12.1 0.3 148 114 45 106 1.47 
49 51779 23 F 3 7.3 0.5 180 122 41 122 5.14 
50 52067 20 F 6 10 0.3 151 102 41 88 2.28 
 
  
S. 
No RCC NO ACLIgG ACLIgM C3 (mg/dl) SLEDAI SLICC Renal 
1 52067 6 9 - 3 0 class 2/5 
2 49464 19 30.9 - 12 1 N 
3 50636 8 6 57.7 17 0 N 
4 51204 15.8 20 - 13 0 N 
5 51109 4.1 9.4 - 8 0 N 
6 49417 2.9 5.4 - 5 0 N 
7 51244 9.4 4.8 82 13 0 N 
8 51270 4.6 3.9 - 16 0 N 
9 49585 16.4 15.6 - 8 1 N 
10 51105 15.6 19 - 13 0 N 
11 51238 8 1.7 64 29 0 N 
12 51242 23.7 20 144 7 0 N 
13 51223 3.2 2.9 126 9 0 N 
14 51188 3.7 4.1 - 11 0 N 
15 51304 5.8 4.6 - 11 0 N 
16 49905 3.5 7.1 166 2 0 N 
17 51242 3.2 2.2 - 7 0 N 
18 51336 8 6.3 - 12 0 N 
19 51305 20.7 35 78 16 0 N 
20 51246 3 7.1 - 10 0 N 
21 50785 5.8 2.9 - 13 0 N 
22 49589 11 7.1 166 6 0 N 
23 51214 6 4.6 - 11 0 N 
S. 
No RCC NO ACLIgG ACLIgM C3 (mg/dl) SLEDAI SLICC Renal 
24 51200 4.1 5.1 - 10 0 N 
25 51360 2.1 9 48 14 0 N 
26 50955 3.5 10 138 13 0 N 
27 51703 6.1 5.1 - 3 0 N 
28 51125 4 6.3 - 16 0 N 
29 50344 5.7 4.6 42 26 0 N 
30 51388 8 2.2 38 24 0 N 
31 51449 4.6 5.3 64 10 0 N 
32 51399 3.2 2.7 - 17 0 N 
33 51445 5.7 5.3 - 11 0 N 
34 51472 4.2 6.3 - 14 0 N 
35 51531 6 4.4 52 16 0 N 
36 51648 8 4.8 - 4 0 N 
37 51622 23.7 15.6 166 5 0 N 
38 50098 3.2 6 - 15 1 N 
39 49510 5 2.2 - 17 0 N 
40 51762 4.1 9 78 9 0 N 
41 51851 8 11.2 - 12 0 N 
42 51831 33.1 15.6 168 11 0 N 
43 51891 4.7 5.4 72 12 0 N 
44 51911 5.8 6.6 - 9 0 N 
45 51630 3.2 1.7 - 9 0 N 
46 51977 8 7.1 152 5 0 N 
S. 
No RCC NO ACLIgG ACLIgM C3 (mg/dl) SLEDAI SLICC Renal 
47 51278 4.7 4 - 5 0 N 
48 51983 3.7 4.8 - 8 0 N 
49 51779 5.8 2.7 58 16 0 N 
50 52067 6.9 12 87 17 0 N 
 
 
S. 
No. OP AGE SEX 
FMD 
(%) IMT (mm) CHOL TGL HDL LDL 
1 15666 23 F 14.3 0.5 183 124 47 110 
2 15668 31 F 17.1 0.4 176 126 44 120 
3 15670 27 F 22.9 0.4 183 123 46 102 
4 15678 25 F 20 0.5 186 128 43 106 
5 15789 34 F 18.9 0.4 184 120 40 110 
6 15899 17 F 21.4 0.3 190 110 41 102 
7 15896 20 F 19.5 0.4 176 110 46 106 
8 15898 21 F 22.8 0.5 194 116 46 110 
9 15977 20 F 17.2 0.3 174 122 47 106 
10 16003 23 F 21.8 0.3 176 130 47 104 
11 16024 21 F 21.6 0.4 183 112 42 110 
12 16026 17 F 22.6 0.3 170 116 46 102 
13 16027 20 F 18.6 0.4 186 124 41 110 
14 16033 19 F 20 0.3 183 126 47 108 
15 16035 18 F 22.9 0.3 156 106 42 102 
16 16045 21 F 20 0.4 170 126 46 112 
17 16098 21 F 21.6 0.4 186 122 42 110 
18 16094 18 F 21 0.4 196 120 44 110 
19 16108 16 F 21.2 0.4 186 102 46 106 
20 16118 25 F 22.2 0.3 176 108 42 106 
21 16128  27 F 20.2 0.4 196 126 42 110 
22 16146 27 F 20 0.4 176 110 44 102 
23 16154 28 F 22.5 0.4 184 126 40 102 
24 16124 18 F 17.5 0.3 186 110 44 112 
25 16134 25 F 17.9 0.4 146 126 40 102 
S. 
No. OP AGE SEX 
FMD 
(%) IMT (mm) CHOL TGL HDL LDL 
26 16213 20 F 17.5 0.3 146 114 42 110 
27 16154 29 F 22 0.3 189 110 40 102 
28 16166 19 F 17.1 0.3 192 116 46 106 
29 16178 23 F 21.2 0.4 124 123 40 112 
30 16188 17 F 21.4 0.3 194 122 42 110 
31 16192 20 F 21.2 0.4 140 102 42 84 
32 16198 28 F 22.2 0.3 146 96 40 110 
33 16233 17 F 18.8 0.4 192 112 40 122 
34 16234 14 F 22.9 0.3 132 114 42 106 
35 16355 30 F 20 0.3 198 106 44 86 
36 16557 16 M 17.6 0.3 188 104 40 106 
37 16559 36 F 18.4 0.3 182 108 40 112 
38 16568 32 F 18.4 0.4 194 106 46 120 
39 16572 19 F 19.4 0.3 192 102 42 112 
40 16576 17 F 15.8 0.3 172 98 42 90 
41 16582 23 F 14.6 0.4 177 102 40 106 
42 16590 22 F 17.9 0.3 169 84 42 102 
43 16592 24 M 15.2 0.3 170 110 48 110 
44 16595 17 M 22.6 0.4 195 102 40 102 
45 16598 28 F 21.9 0.4 118 106 44 90 
46 16599 27 F 20 0.3 188 110 40 98 
47 16702 35 F 19.4 0.4 188 108 42 113 
48 16744 25 F 19.4 0.3 148 106 43 90 
49 16746 29 F 20 0.4 180 113 41 86 
50 16748 23 F 21.2 0.4 151 96 40 88 
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INTRODUCTION 
 Systemic lupus erythematosus (SLE) is an autoimmune disease, with a wide 
range of clinical manifestations. In 1976, Urowitz et al. (1) postulated a bimodal 
mortality pattern in patients with this disease: in the first part of evolution, mortality 
is due to severe infections or to disease activity, but after 5 years of SLE course, 
mortality is caused by the accelerated atherosclerosis and its consequences. With the 
constantly increasing drugs available in the therapeutic armamentarium, even though 
the early mortality has been brought under control, the late mortality and morbidity 
associated with SLE remains at high levels. During the last 3 decades, there have 
been several studies on atherosclerosis in SLE. It has been proved that 
atherosclerosis has a high incidence among young women with SLE. These patients 
have a high prevalence of coronary artery disease and an incidence of myocardial 
infarction up to 50 times higher than age-matched healthy subjects. This high 
incidence of atherosclerosis in SLE cannot be attributed only to traditional risk 
factors (2, 3). 
 Endothelial function is thought to be an important factor in the pathogenesis 
of atherosclerosis, hypertension and heart failure. In healthy subjects, endothelium is 
more than a physical barrier and has several functions, like: a) continuous regulation 
of vascular tone, b) leucocytes adhesion, c) maintenance of the balance between 
thrombotic and anticoagulant properties of the blood (4). When these functions of 
the endothelium are affected, endothelial dysfunction appears. 
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 Endothelial dysfunction is considered as the first step in the atherogenetic 
process. Endothelial dysfunction in SLE is produced by the clustering of traditional 
risk factors, adverse effects of treatment and SLE itself as an independent risk factor 
(5, 6). Systemic inflammation, autoantibodies directed to double stranded DNA 
(dsDNA), ribonucleoproteins (nRNP), endothelial cells, phospholipids, circulating 
immune complexes, activated complement products, lupus nephropathy and 
dyslipidemia represent some factors related to SLE which contribute to appearance 
of endothelial dysfunction (7,8). In the 1990s, high-frequency ultrasonographic 
imaging of the brachial artery to assess endothelium-dependent flow-mediated 
vasodilatation (FMD) was developed. The technique provokes the release of nitric 
oxide, resulting in vasodilatation that can be quantitated as an index of vasomotor 
function. The noninvasive nature of the technique allows repeated measurements 
over time to study the effectiveness of various interventions that may affect vascular 
health (9).  
 Tremendous interest exists in determining the clinical utility of brachial 
artery FMD. Investigators have hypothesized that endothelial function may serve as 
an integrating index of risk factor burden and genetic susceptibility, and that 
endothelial dysfunction will prove to be a preclinical marker of cardiovascular 
disease (10). Several studies suggest that the presence of endothelial dysfunction in 
the coronary circulation is an independent predictor of cardiovascular disease events 
(11, 12). The technique is particularly well suited for study of the earliest stages of 
atherosclerosis in children and young adults, thus providing maximal opportunity for 
prevention. Recently, endothelial dysfunction has also been found in patients with 
systemic vasculitis and has been reversed by administration of immunosuppressive 
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therapy (13). As endothelial dysfunction may represent an early stage in 
atherogenesis, it is important to understand the mechanisms of its development in a 
condition such as SLE. It is also important to determine whether it is associated with 
other CHD risk factors or early atheroma.  
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REVIEW OF LITERATURE 
 SLE predominantly occurs in women, with a gender ratio of 9:1. Onset is 
typically in the age group of 20- 30 yrs. Multiple predisposing factors have been 
identified. The genetic predisposition is complex, likely involving more than 100 
genes. HLA-DR and DQ alleles are associated not just with the risk of developing 
lupus, but with the kinds of autoantibodies produced. Genes that control apoptosis 
(programmed cell death) are important in murine lupus models and likely in human 
lupus as well. The proteins to which the lupus patient mounts an autoantibody 
response are exposed on nuclear blebs during apoptosis. Genes involved in immune 
complex clearance (Fc-gamma receptor alleles) may predispose patients to lupus 
nephritis. Gene expression studies have identified an "interferon signature"—a 
group of genes regulated by interferon-—in the majority of SLE patients. The 
genetic predisposition to SLE is not overwhelming. Only 10% of patients have a 
first-degree relative with SLE, and SLE develops in only 2% of children who have 
an afflicted parent. 
 Environmental factors play a role not only in the onset of SLE but also in 
triggering the "flares" (relapses). The most recognized environmental trigger is 
ultraviolet light exposure. Ultraviolet (UV) light significantly by UV - B can trigger 
photosensitive rashes, and more rarely, systemic flares. SLE patients are more likely 
than controls to have drug allergies, especially to sulfonamide antibiotics. Infection 
with Epstein-Barr virus has been strongly associated with SLE in a multicase family 
registry. Hormonal factors are obviously important, given the female predominance 
of SLE and the usual onset of SLE after puberty. In clinical trials, hormone 
                                                      
 
12
replacement therapy has been associated with increased flares in SLE, but oral 
contraceptives did not. Pregnancy is associated with SLE flares in some, but not all, 
studies. Elevation of prolactin may be associated with activity of SLE. 
 The activity of SLE follows several patterns. The classic pattern, the flare 
pattern, is characterized by a relapsing-remitting course. However, an equal number 
of SLE patients have a pattern of continuously active disease. Only a minority of 
patients have long periods of disease quiescence. The antimalarial drug 
hydroxychloroquine, which is widely used for cutaneous lupus and lupus arthritis, 
reduces future flares if patients continue to take it. Over half of SLE patients have 
acquired permanent damage in one or more organ systems. Although damage, such 
as renal failure and interstitial pulmonary fibrosis, can occur from SLE itself, 
immunosuppressive therapy also contributes to certain damage. For example, long-
term prednisone therapy may cause osteoporotic fractures, osteonecrosis, cataracts 
and glaucoma. 
 Survival of SLE patients peaked at about 80% at 10 years after diagnosis in 
the 1980s. The Centers for Disease Control and Prevention reported in 2002 that 
mortality in young women had actually increased. The major cause of death in SLE 
is accelerated atherosclerosis. Although SLE itself can damage the endothelial 
surface of the coronary arteries, part of the atherosclerotic process results from 
elevated levels of traditional cardiovascular risk factors, including hypertension, 
dyslipidemia, obesity, and homocysteine levels. Prednisolone increases the patient's 
weight, blood pressure, glucose, and lipid levels. SLE nephritis can lead to 
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hypertension and dyslipidemia. Renal insufficiency can increase serum 
homocysteine levels. 
 The description of a bimodal mortality pattern in SLE patients by Urowitz  
et al. in 1976 was an instrumental step toward identifying their increased risk of 
premature atheromatous cardiovascular disease (CVD). Patients who succumbed to 
lupus early in the disease course were noted to die most often from complications of 
disease activity (e.g., organ failure) or therapy. Patients who died later often had 
quiescent disease, and died from CV events. These findings were substantiated by an 
autopsy series reported by Bulkey et al. in which the majority of a cohort of young 
women with a mean age of 35 years had significant obstructive atherosclerotic 
disease of at least one major coronary artery (14). As survival has improved from 
better means of disease detection and treatment, atherosclerotic CVD has emerged 
as a significant cause of morbidity and mortality in SLE. The prevalence of 
cardiovascular and cerebrovascular events in SLE ranges from 6% to 26% (15, 16, 
17, 18, 19, 20, 21, 22, 23 & 24). Ischemic cerebrovascular events (stroke/transient 
ischemic attack) have been reported in 10% to 26%, (17, 18, 22, 23 & 24), whereas 
MI and angina have been reported in 6% to 11% of SLE patients (15, 16, 19, 20, 21, 
22, 23 & 24). 
 Not surprisingly, autopsy studies as well as the examination of surrogate 
markers of coronary atherosclerosis in SLE suggest that the prevalence of 
subclinical atherosclerosis is higher than overt events (14, 25, 26, 27, 28, 29, 30, 31, 
32, 33, 34, 35 & 36). Autopsy studies reveal atherosclerotic disease of the coronary 
arteries in SLE in 22% to 54% of cases (14, 25 & 26). Noninvasive studies 
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including vascular ultrasound, electron beam tomography, and myocardial perfusion 
studies demonstrate atherosclerotic vascular disease in 17% to 40% of SLE patients 
(27, 28, 29, 30, 31, 32, 33, 34, 35 & 36). In a cohort of SLE women with a mean age 
of 44.9 years, 40% were found to have focal carotid plaque as measured by 
ultrasound (27). Another study of 75 SLE women with a mean age of 38.8 years 
demonstrated that 28% had coronary artery calcifications (31). Roman et al. found 
carotid plaque in 37% of SLE patients, compared with a prevalence of 15% in age, 
sex, and race-matched controls (32). 
 A striking feature of this comorbid condition of SLE is its predilection for 
premenopausal women. Ward evaluated rates of hospitalization for cardiovascular 
events in a cohort of SLE women compared to a control group (37). Younger SLE 
women (age 18 to 44) were 2.27 times more likely to be hospitalized with MI and 
3.8 times more for congestive heart failure than controls. In the middle-aged women 
(45 to 64 years), the frequency of hospitalization for heart failure was just 1.39 times 
higher, and the frequency for MI hospitalization did not differ significantly from that 
of controls. A study comparing SLE women with age-similar women from the 
Framingham offspring cohort demonstrated a 50-fold increased risk of MI in the 
SLE women between 35 and 44 years of age (38). In sharp contrast to women in the 
general population, where the risk of atherosclerotic CV events is highest after 
menopause, the mean age at the first event in SLE women was earlier in their life 
(39). 
 
                                                      
 
15
 Traditional risk factors for CVD occur frequently in SLE, both as a 
consequence of disease activity and treatment. The presence of subclinical 
inflammation in the general population has been demonstrated to correlate with the 
development of a number of traditional risk factors, including insulin resistance, 
visceral adiposity and hypertension (40, 41 & 42). It is possible that the sustained 
systemic inflammation and immune activation in SLE has similar influences on the 
development of CV risk factors. The Toronto Risk Factor Study compared 250 SLE 
patients with 250 controls and found that SLE patients had a higher number of CV 
risk factors per patient as well as a higher prevalence of diabetes, hypertension, and 
elevated levels of low-density lipoproteins, triglycerides, and homocysteine (43). 
Additionally, both Bruce et al. and Costenbader et al. have demonstrated that even 
when CV risk factors are identified in SLE patients, they often are not adequately 
treated (44,45). Although a large part of CVD risk in SLE is likely a result of a high 
prevalence of traditional CV risk factors, Esdaile et al. demonstrated that the 
presence of CV risk factors alone does not explain the increased incidence of CV 
events (46). 
 Glucocorticoid therapy has been implicated in atherosclerosis in both lupus 
and nonlupus patients, but it is unclear whether this reflects pro-atherogenic effects 
of the underlying disease process or adverse metabolic effects associated with 
steroid use (47, 48, 49). 
 Antiphospholipid antibodies have been considered as a contributory factor to 
SLE-associated atherosclerotic disease. In addition to their postulated role in arterial 
endothelial damage, they have been associated with renal arterial disease (both 
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thrombotic and stenotic), which may result in hypertension from activation of the 
renal-angiotensinogen-aldosterone axis from renal hypoperfusion (50, 51). Although 
cohort studies have failed to identify an association between the presence of 
antiphospholipid antibodies and surrogate markers of coronary atherosclerosis, there 
is a strong association between surrogate markers of CVD and CV events with 
hypertension with in SLE (22, 52 and 53). The importance of this association 
becomes apparent when more closely evaluated.  
 Cardiovascular disease and atherosclerosis are a common cause of morbidity 
and mortality in various SLE cohorts. Autopsy studies from the early 1980s showed 
severe atherosclerosis in 40% of SLE patients compared with 2% of control subjects, 
matched for age at the time of death. Analysis of the Swedish Hospital Discharge 
Register followed by linkage to the Cause of Death Register during the period 1964 
to 1995 showed that SLE patients were at increased risk for death as a result of 
coronary heart disease or stroke (standardized mortality ratio 2.97, 95% confidence 
interval 2.78 to 3.16). The risk was substantially higher in the younger group of 
patients (20 to 39 years old; standardized mortality ratio 16, 95% confidence interval 
10.4 to 23.6). 
 Other studies have shown that SLE patients carry an increased risk for 
myocardial infarction or stroke compared with the healthy population. This risk 
cannot be fully explained by the traditional cardiovascular disease risk factors.  
Atherosclerosis—defined by coronary artery calcification or carotid plaque size—
also is more common in SLE patients than in healthy controls (e.g., 31% versus 9%, 
in subjects with an average age of 40; relative risk 9.8, 95% confidence interval 2.5 
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to 39), even after adjustment for possible confounding factors, and it correlates with 
disease activity and damage scores.  
Pathogenesis of coronary atherosclerosis in SLE: 
Immune Complex or Arteritis 
 Animal models suggest that this contributes to atherosclerosis. Vascular 
injury, through immune complexes, followed by exposure to atherosclerotic risk 
factors, can lead to atherosclerosis in animal models. Immunization of rabbits with 
heat-shock protein 60/65 leads to aortic intima atherosclerosis. Coronary 
vasculopathy and myocardial infarctions are found in murine lupus models, often in 
association with anticardiolipin antibody. Immune complexes from lupus sera 
accelerated uptake of cholesterol by smooth muscle cells. One small study in human 
SLE suggested that patients treated with corticosteroids had less intimal proliferation 
in their coronary vessels, suggesting that suppression of arteritis initially might lead 
to less atherosclerosis later. 
Anti-phospholipid Antibodies 
 Anti-phospholipid antibodies could contribute to coronary artery disease 
through thrombosis or vasculopathy. The association of anti-phospholipid antibodies 
with coronary artery disease has been shown in some but not all studies. It has been 
found that the lupus anticoagulant is associated with angina/myocardial infarction, 
but not carotid plaque. Lupus anticoagulant was increased in SLE cases with 
cardiovascular disease vs those without. Anti-phospholipid antibodies may function 
also as antibodies against oxidized lipoproteins, an additional mechanism (the 
                                                      
 
18
“oxidative modification hypothesis”) by which they might contribute to 
atherosclerosis. In one study, anti-oxLDL was higher in SLE cases with 
cardiovascular disease. However, several studies have failed to find an association of 
antioxLDL with arterial thrombosis, arterial disease or atherosclerosis. Finally, one 
of the plasma protein targets of antiphospholipid antibodies, b2 glycoprotein I, may 
be an important control against atherosclerosis that is perturbed by anti-phospholipid 
antibodies. Anti-b2 glycoprotein I accelerates uptake of oxLDL in vitro. There is 
also interest in lysophosphatidycholine, LPC, a high-affinity ligand for G2A, a 
lymphocyte expressed protein-coupled receptor. Genetic deletion of the receptor 
results in autoimmunity. LPC is reduced in SLE and anti-LPC has been detected.  
Chronic Infection 
 In the non-SLE patient, there is great interest in chronic infections, including 
Chlamydia pneumoniae, as potential causes of atherosclerosis. Simple antibiotic 
regimens could conceivably eliminate these infections and reduce later coronary 
artery disease. Whether these chronic infections lead to accelerated atherosclerosis 
in SLE is currently unknown. 
Coronary Artery Disease Risk Factors 
 Multiple studies have now proven that the risk of coronary artery disease 
(CAD) in SLE cannot be solely explained by traditional cardiovascular risk factors. 
After controlling for common risk factors at baseline, SLE patients have a relative 
risk of 10.1 for nonfatal MI. In a study with control subjects matched for traditional 
cardiovascular risk factors, SLE patients had more carotid atherosclerosis (41 vs 
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9%) and left ventricular hypertrophy (32 vs 5%). On average, SLE patients with 
coronary artery disease have one less traditional cardiovascular risk factor than a 
control patient. Although traditional risk factors cannot explain all atherosclerosis in 
SLE, they contribute significantly to the process.  
 Several works have found that routine coronary artery disease risk factors are 
very frequent in SLE patients. In fact, the average SLE patient in a cohort study has 
3 or more of these routine CAD risk factors. Some of these risk factors could be due 
to SLE. Hypertension, for example, is more prevalent in SLE patients with renal 
disease. Hypertension is associated with coronary artery disease in SLE, including 
some, but not all, multivariate analyses.  
 Hyperlipidemia in SLE has two major patterns. One pattern occurs in active 
disease, especially in pediatric patients. These patients have low HDL cholesterol 
and apoprotein A1 with elevated VLDL cholesterol and triglyceride levels. Lahita 
and colleagues have found a similar dyslipoproteinemia in SLE patients with anti-
cardiolipin antibody. However, one group has found that disease activity, rather than 
anti-cardiolipin, explains the reduction in HDL. There are likely defects in early 
cholesterol transport and VLDL metabolism associated with active SLE. The second 
pattern occurs in SLE patients on corticosteroids, with higher levels of triglyceride, 
cholesterol, and LDL cholesterol. Sustained hypercholesterolemia, rather than 
baseline, or intermittent elevation, is the most important predictor. A third problem 
identified is decreased lipolysis and chylomicron remnant removal. Lipoprotein (a) 
(Lpa) has been identified as a risk factor for atherosclerosis in SLE. SLE patients 
can make anti-lp (a). Lp (a) may rise with disease flares and be reduced by 
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corticosteroids. SLE patients with higher lp (a) levels also have more immune 
complexes containing b2 glycoprotein I.  
 The major cause of death in lupus nephritis patients is cardiovascular 
disease. Traditional cardiovascular risk factors, especially hypertension and 
hyperlipidemia, are increased. Tubulointerstitial lipid deposits can be found. In 
juvenile-onset SLE, nephrotic range proteinuria is the strongest risk factor for 
atherosclerosis. In a longitudinal study, three CAD risk factors, weight, cholesterol, 
and mean arterial pressure, were worsened by prednisone therapy. In the regression 
model, a 10-mg increase in prednisone led to a 5.5-lb increase in weight and an 8.9-
mg% increase in total cholesterol, adjusting for all other factors known to affect 
these risk factors. Thus, even if the development of these CAD risk factors is 
directly due to SLE, prednisone treatment increases their levels.  
 A recent work has focused on a newly identified risk factor for 
cardiovascular disease, homocysteine. Homocysteine is an amino acid that has a 
direct toxic effect on endothelium and indirect effects, including induction of a 
vascular endothelial cell activator, promotion of vascular smooth muscle 
proliferation, and an inhibitory effect on endothelial cell growth. 
Hyperhomocysteinaemia has been shown to increase the risk of coronary artery 
disease, stroke, and carotid artery stenosis in the Physicians’ Health Study and the 
Framingham Heart Study. In the Hopkins Lupus Cohort Study, 15% of the 337 SLE 
patients had elevated homocysteine. Raised homocysteine levels were significantly 
associated with stroke and arterial thrombosis. A retrospective study has confirmed 
this association. 
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Based on several studies the risk factor frequency can be approximated as follows: 
Risk factor Frequency (%) 
Family history 41 
Hypertension 48 
Hypercholesterolemia 56 
Obesity (major) 38 
Smoking—ever 56 
Smoking—current 35 
Sedentary lifestyle 70 
Diabetes 7 
Homocysteine 15 
 
 Inflammation plays a major role in the pathogenesis of atherosclerosis and 
myocardial infarction in the general population. The benefit of statins, for example, 
is mediated not just by their lipid-lowering effect, but by an anti-inflammatory effect 
(demonstrated by reduction in C-reactive protein) that likely stabilizes plaques. In 
the general population, C-reactive protein, IL-6, fibrinogen, and other markers of 
inflammation are predictive of atherosclerosis. In SLE, C-reactive protein was not 
predictive in a multivariate model nor in univariate analyses in one lupus cohort. 
However, in another case-control study, C-reactive protein was increased in SLE 
cases vs SLE controls. They did not find fibrinogen to be predictive of 
atherosclerosis. In one study, fibrinogen increased with duration of disease 
regardless of disease activity, and was increased in SLE patients with thrombosis.  
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 Prolonged corticosteroid therapy could precipitate atherosclerosis indirectly, 
by increasing the levels of CAD risk factors (hypertension, hypercholesterolemia, 
hypertriglyceridemia, diabetes mellitus, obesity, and homocysteinemia) or directly, 
via vascular injury. Accelerated atherosclerosis has occurred in SLE patients without 
corticosteroid use, but such cases are very rare. In a 1986 review, Nashel made a 
strong case that the latter occurs. In animals, corticosteroids and ACTH produce 
vascular injury, alter vascular connective tissue and worsen experimentally induced 
atherosclerosis. Patients with Cushing’s syndrome, before effective treatment was 
available, commonly developed accelerated atherosclerosis. 
Flow mediated Dilatation:  
 The capacity of blood vessels to respond to physical and chemical stimuli in 
the lumen confers the ability to self-regulate tone and to adjust blood flow and 
distribution in response to changes in the local environment. Many blood vessels 
respond to an increase in flow, or more precisely shear stress, by dilating. This 
phenomenon is designated FMD. A principal mediator of FMD is endothelium-
derived NO. The precise mechanisms for the acute detection of shear forces and 
subsequent signal transduction to modulate vasomotor tone are not fully understood. 
The endothelial cell membrane contains specialized ion channels, such as calcium-
activated potassium channels, that open in response to shear stress (54, 55 & 56). 
The effect of potassium channel opening is to hyperpolarize the endothelial cell, 
increasing the driving force for calcium entry (there are no voltage-gated calcium 
channels in endothelial cells). Calcium activates an enzyme, endothelial nitric oxide 
synthase (eNOS), and the subsequent generation of NO appears to account for FMD 
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(57, 58). Indeed, endothelial denudation or treatment with a nitric oxide synthase 
(NOS) inhibitor abolishes FMD in a variety of arterial vessels. However, it was 
recently shown that blood vessels from mice genetically engineered to lack the 
eNOS enzyme (eNOS knockout mice) still respond to shear stress by dilating. In the 
eNOS knockout mice, FMD seems to be mediated by endothelium-derived 
prostanoids, as it is blocked by indomethacin (59). Thus, there is some redundancy 
in the system, and more than one endothelial mediator is capable of acting as the 
signal between endothelium and smooth muscle. It is unknown whether other 
mediators, such as the putative endothelium-derived hyperpolarizing factor, can 
cause FMD if both NO and prostanoids are deficient.  
 Several mechanisms may underlie the increase in NO in response to changes 
in shear stress. Very acute changes may be mediated by the increase in intracellular 
calcium that occurs when ion channels open (see the previous text). Over slightly 
longer time periods (minutes), shear-stress-induced phosphorylation of eNOS via a 
serine/threonine protein kinase, Akt/PKB, increases eNOS activity, even at low 
calcium concentrations, and this may be important to allow continued output of NO 
(60, 61). In addition, other posttranslational modifications of the enzyme 
(myristilation or palmitoylation) or interaction with caveolin can affect intracellular 
localization of the enzyme and thereby alter its function. Over longer time periods 
(many minutes or hours), eNOS gene transcription is activated, and this can result in 
continued increases in NO generation if shear stress is maintained at high levels.  
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 To assess endothelial function noninvasively, brachial arteries are scanned 
with high resolution ultrasound imaging, under baseline conditions (at rest) and 
during hyperemia induced by inflation and deflation of a sphygmomanometer cuff 
mostly around the forearm distal to the site to be scanned with ultrasound. The 
induced shear stress caused by the increased blood flow following transient ischemia 
induces nitric oxide (NO) release, which in turn causes local arterial vasodilatation. 
Endothelial function, defined as flow mediated dilatation (FMD), is estimated as the 
percentage increase in vessel diameter from baseline conditions to maximum vessel 
diameter during hyperemia. Impaired endothelial function of the brachial artery 
assessed in this manner has been reported in asymptomatic children and adults with 
elevated cardiovascular risk factors such as smoking (62), hypercholesterolemia 
(63), hypertension (64), diabetes mellitus (65), and hyperhomocysteinaemia (66). 
Although the results of these studies are likely to be internally valid, comparison of 
the FMD values across studies is troublesome. FMD values vary considerably across 
populations, ranging from –1.9 to 19.2%.  
 Masoud El-Magadmi et al (67) studied 62 women with SLE (1997 revised 
criteria) and 38 healthy women. Demographic and risk factor data were collected. In 
patients, disease activity and treatment-related parameters were also assessed. 
Endothelial function was assessed by flow-mediated dilation (FMD) in the brachial 
artery in response to reactive hyperemia. Carotid intima-media thickness (IMT) and 
the presence of carotid plaques were also assessed in SLE patients. FMD was 
impaired in SLE patients (median, 3.6%; range, –6.3% to 13.7%; versus median, 
6.9%; range, –6.6% to 17.8%, P<0.01). Using multiple regression analysis that 
included all subjects in which they retained all the classic CHD risk factors, they 
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found that systolic blood pressure (P=0.019) and SLE (P=0.017) were significantly 
associated with impaired FMD. Within SLE patients, IMT showed a negative 
correlation with percent FMD (r=–0.37, P<0.01). In stepwise multiple regression of 
SLE patients only, that also included SLE factors and IMT, IMT alone was 
independently associated with FMD (P=0.037).  Two other studies have reported 
similar findings. In a study from Sao Paulo, Lima et al noted that the mean± SD 
FMD in SLE was 5.0±5.0% compared with 12.0±6.0% in healthy control subjects. In 
this study, postmenopausal women and subjects with known CHD risk factors were 
excluded. Piper et al found in a UK cohort that SLE women had a median FMD of 
5.6 (interquartile range [IQR], 3.1% to 7.2%) compared with 8.0% (IQR, 6.3% to 
9.3%) in control subjects. 
 Valdivielso P et al (68) analyzed endothelial function in systemic lupus 
erythematosus (SLE), and its relationship with disease activity and subclinical 
arteriosclerosis. They studied a group of 26 patients with SLE and 21 age- and sex-
matched controls. None of the patients or controls had had any ischemic event. Data 
were recorded on medical history, anthropometrics, prior treatment and the lupus 
activity index (LAI). Endothelial function was quantified by flow-mediated 
dilatation in the brachial artery. The presence of subclinical arteriosclerosis was 
assessed by the average intima-media thickness (IMT) on carotid ultrasound. The 
patients and the controls had a similar degree of carotid IMT (0.58+/-0.08 mm vs. 
0.57+/-0.07 mm, NS) and a similar prevalence of carotid plaque (27% vs. 24%, NS). 
However, the SLE patients had worse endothelial function than the controls (FMD 
12.4+/-4.4% vs. 16.9+/-5.5%, p<0.05). This difference remained after adjusting for 
age, smoking, body mass index, waist circumference, total cholesterol, triglycerides, 
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HDL cholesterol, apolipoproteins A-1 and B100 and postmenopausal status. A 
significant association was found in the SLE patients between FMD and LAI 
(Spearman Rho -0.462, p<0.05). SLE-associated endothelial dysfunction was 
present in patients who have no prior ischemic events and with the same degree of 
subclinical arteriosclerosis as controls. Moreover, the endothelial dysfunction was 
significantly associated with the degree of disease activity. There was difference 
among these studies with regard to the inclusion of disease duration, comorbities & 
use of immunosuppressants.  
 Piper M K et al (70) compared thirty-six female SLE patients with 22 
healthy age and sex matched controls. Endothelial dependent vasodilatation (EDD) 
was assessed at the brachial artery in response to shear stress. SLE patients showed 
significantly impaired endothelial function (median EDD 5.6%, IQR 3.1-7.2%) 
compared with healthy controls (median EDD 8.0%, IQR 6.3-9.3%; P = 0.001).  
 Zahra Seyyedbonakdar et al (69) evaluated the prevalence of vascular 
endothelial dysfunction and its risk factors in SLE women and then to identify its 
correlation with the disease activity, duration and concomitant conditions in these 
patients. Eighty four female SLE patients and 18 healthy young female were 
included in the study. The vascular endothelial function was evaluated via 
ultrasonographic assessment of the brachial artery diameter to determine flow 
mediated dilation (FMD). SLE patients had higher prevalence of impaired FMD 
than healthy subjects (48.8 vs. 5.5 %). But FMD impairment did not have any 
significant correlation with disease activity, duration, the presence of the anti-
dsDNA, anticardiolipin antibodies, antiphospholipid syndrome, hypertension, 
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hyperlipidemia, diabetes mellitus, hypothyroidism, history of lupus nephropathy, 
and history of receiving cyclophosphamide pulses. 
 Elizabeth Turner et al (71) measured flow-mediated dilation of the brachial 
artery using high resolution ultrasound and the presence or absence of coronary 
calcification by electron beam computed tomography. Twenty patients (17 female) 
median age (interquartile range) 42.5 (32.0–47.5) years were studied. The median 
flow-mediated vasodilatation was 3.6% (1.7%–7.7%). In patients with coronary 
calcification (n = 6), flow-mediated dilation was 2.1% (−0.42%–3.6%) compared 
with 4.0% (3.5%–8.3%) in those without (p = 0.12). There was no significant 
relationship between flow-mediated dilation and markers of disease activity, 
duration of disease, and cardiovascular risk factors. Lower flow-mediated dilation 
was associated with duration of corticosteroid therapy.  
 Lai-Shan Tam et al (72) examined whether acute hyperhomocysteinaemia 
exacerbates endothelial and platelet dysfunction in patients with SLE.  Twelve SLE 
patients and 15 controls were recruited. Oral methionine was used to achieve acute 
hyperhomocysteinaemia. Endothelial function was assessed by flow-mediated 
dilatation (FMD) of the brachial artery; also assessed were the levels of von 
Willebrand factor (vWF) and plasminogen activator inhibitor type 1 (PAI-1). 
Platelet activation was assessed by the levels of beta-thromboglobulin (beta-TG), 
fibrinogen binding, and P-selectin expression using flow cytometry. After oral 
methionine loading, vWF levels increased significantly, whereas FMD remained 
unchanged in both groups. PAI-1 increased significantly only in controls. Fibrinogen 
binding to platelets increased significantly only in SLE patients. Beta-TG remained 
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unchanged in SLE patients but increased significantly in controls. Platelet P-selectin 
expression did not change in either group. These results suggest that the 
prothrombotic tendency after acute hyperhomocysteinaemia is mediated by 
endothelial dysfunction and platelet activation in patients with SLE and healthy 
controls. 
 Parasar Ghosh et al (73) studied Asian Indians with SLE, to find out the 
prevalence and predictors of carotid intima-medial thickness (IMT) and brachial 
artery flow-mediated dilatation. Endothelial dysfunction was assessed by FMD in 
brachial artery and IMT was measured in common carotid artery in SLE patients and 
healthy controls. Sixty SLE patients (mean age 31±9 years) and 38 healthy controls 
(mean age 34±6 years) were included. The IMT was higher in SLE patients as 
compared to controls (0.49±0.08 mm vs. 0.39±0.05 mm, p<0.0001). SLE and 
damage were independent predictors of abnormal IMT. FMD was impaired in SLE 
patients compared to controls (9.97% vs. 18.97%, p<0.00001). None of the classical 
cardiovascular risk factors were predictors of FMD or abnormal IMT. Their study 
has shown a good negative correlation between brachial FMD and carotid IMT 
which have also been shown in other studies (74). 
                                                      
 
29
Guidelines for the ultrasound assessment of endothelial-dependent flow-
mediated vasodilation of the brachial artery (9). 
Mary C. Corretti, MD et al has led the report submitted by the International 
Brachial Artery Reactivity Task Force.  
Subject preparation:   
 Numerous factors affect flow-mediated vascular reactivity, including 
temperature, food, drugs and sympathetic stimuli, among others. Therefore, subjects 
should fast for at least 8 to 12 h before the study, and they should be studied in a 
quiet, temperature-controlled room. All vasoactive medications should be withheld 
for at least four half-lives, if possible. In addition, subjects should not exercise, 
should not ingest substances that might affect FMD such as caffeine, high-fat foods 
and vitamin C or use tobacco for at least 4 to 6 h before the study.  
Equipment:    
 Ultrasound systems must be equipped with vascular software for two-
dimensional (2D) imaging, color and spectral Doppler and a high-frequency vascular 
transducer. A linear array transducer with a minimum frequency of 7 MHz, attached 
to a high-quality mainframe ultrasound system, is used to acquire images with 
sufficient resolution for subsequent analysis. Image resolution is enhanced with 
broadband (multiple-frequency: 7 to 12 MHz) linear array transducers. 
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Image acquisition:    
 The subject is positioned supine with the arm in a comfortable position for 
imaging the brachial artery. The brachial artery is imaged above the antecubital 
fossa. A segment with clear anterior and posterior intimal interfaces between the 
lumen and vessel wall is selected for continuous 2D grayscale imaging. 
 Endothelium-dependent FMD: To create a flow stimulus in the brachial 
artery, a sphygmomanometric (blood pressure) cuff is first placed either above the 
antecubital fossa or on the forearm. A baseline rest image is acquired, and blood 
flow is estimated by time-averaging the pulsed Doppler velocity signal obtained 
from a midartery sample volume. Thereafter, arterial occlusion is created by cuff 
inflation to suprasystolic pressure. Typically, the cuff is inflated to at least 50 mm 
Hg above systolic pressure to occlude arterial inflow for a standardized length of 
time. This causes ischemia and consequent dilation of downstream resistance vessels 
via autoregulatory mechanisms. Subsequent cuff deflation induces a brief high-flow 
state through the brachial artery (reactive hyperemia) to accommodate the dilated 
resistance vessels. The resulting increase in shear stress causes the brachial artery to 
dilate. The image of the artery is recorded continuously from 30 s before to 2 min 
after cuff deflation. 
 Studies have variably used either upper arm or forearm cuff occlusion, and 
there is no consensus as to which technique provides more accurate or precise 
information. When the cuff is placed on the upper part of the arm, reactive 
hyperemia typically elicits a greater percent change in diameter compared with that 
produced by the placement of the cuff on the forearm (75, 76 & 77). This may be 
                                                      
 
31
due to a greater flow stimulus resulting from recruitment of more resistance vessels 
or possibly to direct effects of ischemia on the brachial artery. However, upper-arm 
occlusion is technically more challenging for accurate data acquisition as the image 
is distorted by collapse of the brachial artery and shift in soft tissue. The change in 
brachial artery diameter after cuff release increases as the duration of cuff inflation 
increases from 30 s to 5 min. The change in diameter is similar after 5 and 10 min of 
occlusion; therefore, the more easily tolerated 5-min occlusion is typically used. 
Also, FMD may be studied in the radial, axillary and superficial femoral arteries. 
Notable caveats are that arteries smaller than 2.5 mm in diameter are difficult to 
measure and vasodilation is generally less difficult to perceive in vessels larger than 
5.0 mm in diameter (78, 79 & 80). 
Anatomic landmarks:    
 The diameter of the brachial artery should be measured from cross sectional 
images in which the lumen-intima interface is visualized on the near (anterior) and 
far (posterior) walls. These boundaries are best visualized when the angle of 
insonation is perpendicular. Thus, clear visualization of both the near and far wall 
lumen-intima boundaries indicates that the imaging plane is bisecting the vessel and 
diameters measured from these images likely reflect the true diameter. Once the 
image for analysis is chosen, the boundaries for diameter measurements are 
identified manually with electronic calipers or automatically using edge-detection 
software. The variability of the diameter measurement is greatest when it is 
determined from a point-to-point measurement of a single frame, and least when 
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there is an average derived from multiple diameter measurements determined along 
a segment of the vessel.  
 The diameter measurement along a longitudinal segment of vessel is 
dependent upon the alignment of the image. Skew occurs when the artery is not 
completely bisected by the plane of the ultrasound beam. With slight skew, the 
maximal diameter measured is constant, and thus yields a more accurate 
measurement. Some edge-detection programs can account for skew from transducer 
angulation (79, 81).  
Timing of FMD:    
 Flow-mediated vasodilation is an endothelium-dependent process that 
reflects the relaxation of a conduit artery when exposed to increased shear stress. 
Increased flow, and thereby increased shear stress, through the brachial artery occurs 
during post occlusive reactive hyperemia. Several studies have suggested that the 
maximal increase in diameter occur approximately 60 s after release of the occlusive 
cuff, or 45 to 60 s after peak reactive hyperemic blood flow (80, 82). The increase in 
diameter at this time is prevented by the NOS inhibitor NG-monomethyl-L-arginine, 
indicating that it is an endothelium-dependent process mediated by NO (83, 84). 
Other measures of vasodilator response include time to maximum response (85), 
duration of the vasodilator response and the area under the dilation curve. 
Characterizing FMD:    
 Flow-mediated vasodilation is typically expressed as the change in post-
stimulus diameter as a percentage of the baseline diameter (86).  
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Evaluating precision of the technique:    
 Intraobserver and interobserver variability in image acquisition and analysis 
should be established and periodically reassessed for each condition, including 
baseline, reactive hyperemia and NTG administration. The highest reproducibility is 
likely to be shown over a short interval, during which the individual vasodilator 
response is unlikely to have changed owing to environmental or other influences. 
This can be accomplished by taking two measurements on the same day within a 10- 
to 15-min interval, or on separate days in otherwise identical circumstances. 
Longitudinal studies in which interventions over weeks to months are tested require 
that reproducibility measurements be performed at longer intervals. The image 
analysis and measurement of the vasodilator response from repeated studies should 
be performed by an individual who is blinded as to sequence. Measurement 
variability is assessed, typically, by a designated core laboratory for multicenter 
trials, prior to site certification and periodically thereafter to analyze for temporal 
drifts. Assessment of FMD of the brachial artery in clinical trials has increased 
because of its seeming ease of use, efficiency and noninvasive nature. Owing to the 
biological and technical variability of the measurement, several caveats should be 
considered when planning a clinical trial where FMD is the end point of interest. 
These include study design, sample size and uniform technique.  
Study design:  
 Recent studies have reported on the effect of pharmacologic or physiologic 
interventions on FMD of the brachial artery. These include both acute (87, 88, 89) 
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and longer-term intervention trials (90, 91&92). Both parallel-group and crossover 
designs have been successfully employed.  
Sample size.    
 Typically, significant improvement in FMD can be seen with 20 to 30 
patients in a crossover design study and 40 to 60 patients in a parallel-group design 
study. In studies of this size, the minimal statistically significant improvement that 
can be detected with intervention is an absolute change in FMD of 1.5% to 2%. The 
sample size depends greatly on the variance of repeated measurement in the control 
group in a particular vascular laboratory. 
 With intervention trials, an important parameter to report is the time-
dependent reproducibility of FMD. For example, in the placebo group, the 
pretreatment and post intervention FMD measures are usually reported, and often 
are very similar. However, if the mean difference between the two measurements for 
each patient is quite high, it indicates that the variance of the technique might limit 
interpretation of the study results. An acceptable reproducibility is a mean difference 
of 2% to 3% in FMD over time (on a baseline vasodilation of about 10%) (93). This 
value has not been readily available in published trials.  
Methodology:    
 As discussed above, several techniques have been employed to measure 
FMD (94, 95). Laboratories should select the method that gives them the most 
reproducible results, and for multicenter studies, the same scanning protocol should 
be employed at all sites. For studies employing repeated measurements following 
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intervention, FMD might change as a result of the intervention. However, FMD 
could also be affected by a change in the hyperemic stimulus. Therefore, the flow 
stimulus should be consistent. Otherwise, any change in FMD of the conduit artery 
may be related to changes in flow (indirectly mediated by changes in the 
microcirculation) rather than improvement of endothelial function of the conduit 
vessel per se.  
 Ultrasound assessment of brachial artery FMD has yielded important 
information about vascular function in health and disease, yet several new 
approaches and technological advances have emerged. Most prior studies examined 
FMD at a single time point, typically 1 min after cuff release. This practice evolved 
from the observations that the maximal dilator response occurs at approximately 1 
min in healthy subjects (96) and that the necessity for manual acquisition and 
measurement placed a practical limit on the number of image frames that could be 
analyzed.  
 Commercially available technology now makes it possible to acquire 
multiple images of the brachial artery automatically using the ECG signal as a 
trigger and to measure arterial diameter automatically using computer-based edge-
detection techniques. This approach allows investigators to examine the entire time 
course of brachial dilation in response to reactive hyperemia, the true peak response, 
the time to peak and the overall duration of FMD as discussed in the previous text. 
The time course and extent of brachial expansion within a single cardiac cycle, 
possibly reflecting vessel compliance, can be examined. In the carotid artery, 
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compliance has been shown to correlate with cardiovascular risk (97). About 70% of 
the dilation observed 1 min after cuff release is attributable to NO synthesis (98, 99).  
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AIM OF THE STUDY 
1)   To evaluate endothelial function and to assess the extent of dysfunction in 
newly diagnosed SLE patients by using the measures of flow mediated 
dilatation of the brachial artery and carotid intima media thickness. 
2)  To study the correlation of flow mediated dilatation with carotid intima 
medial thickness.  
3)  To study the relationship between endothelial dysfunction and clinical 
characteristics of SLE. 
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MATERIALS AND METHODS 
Inclusion Criteria: 
1) Newly diagnosed SLE patients by ACR criteria of age 16 yrs and above. 
Exclusion Criteria: 
1) Patients with co morbidities like hypertension, diabetes mellitus and 
hyperlipidemia.  
2) Patients with history of cardiovascular disease (angina, myocardial infarction, 
congestive cardiac failure).     
3) Patients with renal failure (creatinine >3 mg/dl or creatinine clearance <30 
ml/min). 
4) Patients who were on long term medications like prednisolone, other 
immunosuppressants & statins prior to our evaluation. 
5) Patients with clinical evidence of upper limb vascular insufficiency in the form 
of pre gangrene or gangrene. 
6) Patients with overlap syndrome. 
7) Infections in the previous four weeks. 
8) Pregnancy or lactation in the previous 6 weeks. 
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Subjects: 
 Patients were recruited from the rheumatology outpatient clinic and wards of 
Government General Hospital, Chennai, during the period February 2009- February 
2010.   Fifty eligible patients older than 16 years of age were enrolled. They fulfilled 
at least four classification criteria for systemic lupus erythematosus by 1997 ACR 
revised criteria, with no known preexisting cardiovascular disease; and were willing 
to undergo measurement of flow-mediated dilation. 
 Healthy control subjects were recruited from the clinically normal secretarial 
and support staff as well as from friends of patients. All subjects gave written 
informed consent to take part in this study, which was approved by the ethical 
committee.  
Clinical and Laboratory Assessment: 
 All subjects had a detailed history and examination to look for traditional 
cardiovascular disease risk factors, vasculitis, Raynaud’s phenomenon, and 
secondary antiphospholipid syndrome. In patients, disease activity and cumulative 
damage were assessed by the SLE Disease Activity Index (SLEDAI) and the 
Systemic Lupus International Collaborating Clinics (SLICC) respectively. 
Laboratory evaluations include complete blood count, ESR (Westergren’s method), 
liver function test, renal function test, fasting blood sugar and lipid profile. 
Immunological assay were CRP (Latex agglutination method); ANA (CalBiotech 
Inc ANA Screen ELISA kit); Anti dsDNA (Wampole laboratories dsDNA ELISA 
test); Anti cardiolipin antibody (CalBiotech cardiolipin IgG & IgM ELISA kit) & 
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C3, C4 complement levels (Nephelometry). The lupus anticoagulant study was done 
with the dilute Russell viper venom test & activated partial thromboplastin time; 
were also assayed.  
ELISA results were interpreted as follows: 
ANA 
< 0.9 – Negative. 
0.9- 1.1 - Borderline positive. 
> 1.1 - Positive. 
 
Anti dsDNA 
< 0.9 - Negative 
0.91 – 1.09 – Equivocal 
> 1.1 – Positive. 
ACL IgG  
< 10 GPL– Negative 
10- 15GPL – Borderline positive. 
15- 80 GPL– Moderate positive. 
>80 GPL– High positive.  
ACL IgM 
< 15 MPL – Negative 
15- 20 – Borderline positive 
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21- 80 – Moderate positive 
> 80 – High positive. 
Complement Assay (Nephelometry) 
Normal range: 
C3 - 88 – 201 mg/dl. 
C4 – 16 – 47 mg/dl. 
 All patients had Electrocardiogram, chest X ray, ultrasound abdomen and an 
Echocardiogram done by a cardiologist. 
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Assessment of Endothelial Function: 
 Endothelial function was assessed with high-resolution B-mode Doppler 
(Siemens Alterces with a 7.5 MHz linear-array transducer Photo (A))   examination 
of the brachial artery using the protocol described as in the guidelines cited above 
(9). We measured flow-mediated dilation (FMD) in response to reactive hyperemia. 
All subjects were studied between 8 and 11 AM after a12-hour overnight fast. They 
were asked not to smoke on the morning of study and to avoid alcohol for 48 hours. 
The brachial artery was scanned 10 cm above the antecubital fossa (Photo B). 
Distance measured was from anterior to posterior M lines (media-adventitia 
interface), and every measurement was taken by sonologist blinded to cases and 
controls. Then, ischemia was induced by inflating the pneumatic cuff to a pressure 
50 mmHg above systolic one, in order to obliterate the brachial artery. After 5 
minutes, the cuff was deflated and the diameter was measured after 60 seconds post-
deflation (Df).  
 FMD is calculated as follows: 100 %x [(post deflation diameter–resting 
diameter)/resting diameter]. To assess reproducibility of our technique, we looked at 
the reliability of reading scans on 2 separate occasions by a single blinded observer. 
For this, 15 scans from patients or control subjects were chosen at random. The 
intraclass correlation coefficients for resting diameter and FMD were 0.93 (95% CI, 
0.56 to 0.95) and 0.82 (95% CI, 0.30 to 0.97), respectively.  
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Carotid Artery Intima -Media Thickness and Plaque:  
 Patients and control subjects also had the intima-media thickness (IMT) of 
their carotid artery measured using high-resolution B-mode Doppler (Siemens 
Alterces with a 3-15 MHz linear-array transducer). The common carotid artery was 
scanned longitudinally, and the IMT measurement was taken in the proximal part of 
the common carotid artery, 1 cm proximal to the carotid bulb as the maximum 
distance between the intima-lumen and adventitia-media interfaces in areas without 
carotid plaque (100). IMT was determined as the average of 6 measurements, 3 each 
from the left and right common carotid arteries. This is shown in the Photo E. 
 We also noted the presence or absence of carotid plaques, with plaque being 
defined using the criteria described by Li et al (101). The intraclass correlation 
coefficient for IMT measurements, assessed in 15 subjects on 2 separate occasions 2 
weeks apart, was 0.92 (95% CI, 0.84 to 1.00).  
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Statistical Analysis 
 The statistical analysis was performed using the SPSS (version 17.0).  
Results are presented as mean ± SD, except for frequencies, which are 
expressed as percentages.  
Unpaired student’s t- test has been used for comparing the FMD, carotid 
IMT and other features of the study and control group. 
 p < 0.05 was considered statistically significant.     
Pearson’s test has been used for studying the correlation between flow 
mediated dilatation and variables.  
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RESULTS 
 The demographic, clinical and investigation features of the studied groups 
were as follows: 
                                  TABLE 1:  Characteristics of the group 
Parameter Patient (n=50) Control (n=50) P value 
Male/Females 3/47 3/47 1.00 
Mean Age (yrs) 23 ± 5.41 23  ± 5.41 1.00 
BMI (kg/m2) 19.6 ± 1.77 20 ±  1.71 0.31 
Mean duration of  
symptoms (months) 
7.3 0 - 
Systolic BP (mmHg) 112 ± 8.03 111 ±  7.7 0.59 
Diastolic BP (mmHg) 79.6 ±  5.83 79.2 ±  5.52 0.75 
Total Cholesterol 
(mg/dl) 
169 ± 23.4 175 ± 19.7 0.13 
Triglycerides (mg/dl) 114 ± 11.9 113 ± 10.2 0.56 
HDL (mg/dl) 43.6 ±  3.5 42.9 ±  2.51 0.20 
LDL (mg/dl) 108 ± 10.3 105 ± 8.61 0.09 
 
 There were 47 females and 3 males, who were age and sex adjusted in the 
patient and control group. The mean duration of disease according to the onset of 
symptoms, was 7.3 months with a minimum duration of one month to a maximum of 
14 months. There was no statistically significant difference with regard to the blood 
pressure and fasting lipid profile between both the groups.  
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Clinical characteristics of the SLE patients: 
 The patient group had the following clinical features in the proportion given: 
mucocutaneous – 88% (n=44); constitutional – 86% (n=43); musculoskeletal – 41% 
(n=82%); serositis – 22% (n=11); hematological – 6% (n=12%); neuropsychiatric – 
8% (n=4); renal – 2% (n=1); Raynaud’s – 0. The mean SLEDAI score was 11.6.The 
median SLEDAI score was 11 (range, 3 to 29). The median SLICC was 0 (range 0 
to 1). Since we had chosen patients at diagnosis, and by excluding the patients who 
had been on immunosuppressants prior to our evaluation, we had a relatively naïve 
population who had not been on specific disease modifying drugs.  
 On evaluation, the patient population had the following immunological 
features. 
             TABLE 2: Immunological profile the patient group was as follows: 
Parameter Patient group (n=50) 
ANA 100% (n=50) 
Anti dsDNA 78% (n=39) 
Low C3/C4 assay 36% (n=18) 
ACL IgG/IgM  16% (n=8) 
LAC 10% (n=5) 
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TABLE 3: Study characteristics in the patient and control group 
Parameter Patient group Control group p value 
Baseline Diameter 
(mm) 
3.64± 0.40 3.67 ± 0.34 0.64 
FMD (%) 12 ± 3.92 19.8 ± 2.27 < 0.001 
Carotid IMT (mm) 0.38 0.36 0.09 
 
 The patients and the controls had a similar degree of baseline diameter of the 
brachial artery (3.64 ± 0.40 vs. 3.67 ± 0.34 mm, p = 0.64) and carotid IMT (0.38 ± 
0.08 vs. 0.36   ± 0.06, p value 0.09). However, the SLE patients had worse 
endothelial function than the controls (FMD 12 ± 3.92% vs. 19.8 ± 2.27%, p<0.001). 
The endothelial function, assessed by vascular ultrasonography on brachial artery, is 
shown (Baseline Photo (C) & post dilatation Photo (D). The carotid IMT 
measurement is shown in Photo (E). 
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Correlations between FMD and SLE parameters: 
 The correlations between FMD and biological and immunological 
parameters are shown in Table 4. 
TABLE 4: Parameter Correlation coefficient 
Disease duration                                     r = 0.0998                             p = 0.49 
Carotid IMT                                           r = – 0.1993                          p = 0.16 
SLEDAI                                                   r = – 0.5678                          p = <0.01    
C3                                                             r =    0.9101                          p = < 0.01     
Anti dsDNA antibodies                          r =  – 0.8658                         p = <0.01      
Total cholesterol                                     r =  0.0239                            p = 0.86       
ACL IgG                                                 r =  0.2388                             p = 0.09        
ACL IgM                                                 r =  0.2149                            p = 0.13        
 
 The statistical analysis showed an inverse correlation between FMD and 
antidsDNA and SLEDAI which is significant statistically. Similarly there is strong 
positive correlation between FMD and C3.  But, correlation does not imply 
causation.                        
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The size of any correlation generally evaluates as follows: 
Value of r Qualitative Description of the 
Strength 
–1 perfect negative  
(–1, –0.75) strong negative  
(–0.75, –0.5) moderate negative  
(–0.5, –0.25) weak negative  
(–0.25, 0.25) no linear association  
(0.25, 0.5) weak positive  
(0.5, 0.75) moderate positive  
(0.75, 1) strong positive  
1 perfect positive  
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DISCUSSION 
 The patients with SLE have a high incidence of atherosclerosis with its main 
consequence: coronary artery disease. Epidemiological studies have shown that SLE 
women aged 35 – 44 years were over 50 times more likely to develop myocardial 
infarction than women of similar age from general population (3). Anatomo-
pathological investigations have revealed that the SLE patients were prone to 
develop a premature atherosclerosis (102). The increased risk of atherosclerosis is 
not exclusively related to traditional risk factors alone (103). In the last years, SLE 
itself appeared like an independent risk factor for atherosclerosis, acting through 
autoimmune vascular injury (6). In patients with systemic lupus erythematosus, 
atherosclerosis has a long period of subclinical evolution. The first reversible step in 
the atherogenesis process is represented by the endothelial dysfunction (104).  
 Endothelial dysfunction is well described entity in connective tissue diseases, 
leading to accelerated atherosclerosis and associated morbidity and early mortality. 
There are several associated factors like body mass index, co morbidities, 
immunosuppressants, dyslipidemia, hypertension which could contribute to the 
endothelial dysfunction. Our study was designed to first identify the prevalence of 
this in our patients and more importantly attempt to delineate the disease 
contribution from all associated factors. In this regard, we have chosen newly 
diagnosed cases who have not been on treatment and have excluded other associated 
factors like hypertension, dyslipidemia & diabetes mellitus. We could thereby to an 
extent, isolate the disease related factor and attribute the endothelial dysfunction to 
it. 
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 Endothelial dysfunction appears when the normal functions of the 
endothelial cells (control of vascular tone and blood pressure, regulation of 
leucocytes traffic from the blood to the tissues, and platelet adhesion and 
aggregation, maintenance of the balance between blood coagulation and fibrinolysis, 
control of growth, development and differentiation of the vessel wall cells) are lost 
or dysregulated (105). A non-invasive method for the assessment of endothelial 
dysfunction is represented by flow mediated vasodilation (endothelium dependent 
dilation) (106). In our study, FMD in SLE patients was significantly lower than in 
control subjects (FMD 12±3.92% vs. 19.8±2.27%, p<0.001). There are several 
studies with similar results, starting with the first study, performed by Lima et al. 
(107), who showed that SLE patients presented lower FMD than sex and age-
matched controls (5.0±5.0% vs. 12.0± 6.0%) , even in subjects without traditional 
cardiovascular risk factors (70). Tani et al. (16) identified the same pattern of FMD 
in SLE patients as well as by Valdivielso et al (68) (FMD 12.4+/-4.4% vs. 16.9+/-
5.5%, p<0.05). The reduced values of FMD in patients with SLE were found by 
Piper and Turner in their studies, too (67, 71). Our study concurred with the FMD 
results of the other indian study done by Parasar Ghosh et al (73) which was 
impaired in SLE patients compared to controls (9.97% vs. 18.97%, p < 0.00001).  
 The Carotid IMT values showed no significant difference in our study and 
control population (0.38 ± 0.08 vs. 0.36   ± 0.06, p value 0.09). Similar results were 
obtained in the study done by Valdivielso et al (68) (0.58+/-0.08 mm vs. 0.57+/-
0.07 mm, NS).  Parasar Ghosh et al (73) have reported higher carotid IMT in SLE 
patients as compared to controls (0.49 ± 0.08 mm vs. 0.39 ± 0.05 mm, p < 0.0001) and 
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had shown a good negative correlation between brachial FMD and carotid IMT, 
which was not the case in our study. Masoud El-Magadmi et al (67) & Zahra 
Seyyedbonakdar et al (69) also observed a negative correlation with percent FMD 
in their studies. The reason for this difference could be that in early stages of the 
disease to which our patients belonged to, identification of a functional abnormality 
(FMD) would have preceded the structural changes that occur in the carotid arteries 
in the form of intima medial thickness that occurs on a later stage. Moreover the 
other factors which would contribute to subclinical atherosclerosis like comorbities, 
immunosuppressants were not excluded in their studies as against ours. 
 We found a moderate negative correlation between FMD and SLEDAI (r = – 
0.7321, p < 0.001). This correlation between FMD and the disease activity was 
identified in other studies (96, 108 & 109). Valdivielso et al (68) also have reported 
significant correlation between FMD and LAI (Lupus Activity Index). AntidsDNA 
had a strong negative correlation, while C3 complement assay had strong positive 
correlation with flow mediated dilatation. There was no linear correlation between 
other factors like disease duration, cholesterol, anticardiolipin antibodies.  
 When comparing our study with the other indian study done by Parasar 
Ghosh et al (73) regarding other factors, our study population has less disease 
duration ( mean 7.3 months) when compared to their patient population ( mean 60 
months). Similarly their patient population had co morbidities (hypertension, 
diabetes mellitus, dyslipidemia), and had been exposed to several 
immunosuppressants. These factors have their contribution in the endothelial 
dysfunction.   
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 FMD using vascular ultrasonography on brachial artery represents a useful, 
non-invasive method for the assessment of the endothelial dysfunction. Reactive 
hyperemia produces a shear stress stimulus that induces the normal endothelium to 
release nitric oxide (NO), which acts as a vasodilator. Impaired endothelial function 
is associated with a reduced release of NO and a lower vasodilation (110). The effect 
of disease states and/or interventions on the blood flow response to cuff occlusion 
(reactive hyperemia) is under explored. Current technology limits the utility of 
spectral Doppler to reproducibly assess changes in flow, which might provide useful 
information about endothelial function of the microvasculature.  
 Ongoing studies in several large populations, including the Framingham 
Heart Study and the Cardiovascular Health Study, shall determine whether 
endothelial dysfunction in the brachial artery will identify patients at risk for 
developing coronary artery disease, cerebral vascular disease and/or peripheral 
vascular disease. The technique is particularly well suited for study of the earliest 
stages of atherosclerosis in children and young adults, thus providing maximal 
opportunity for prevention.  
 Numerous studies have demonstrated that brachial artery reactivity improves 
with risk factor modification and treatment with drugs known to reduce 
cardiovascular risk. It remains unknown whether an improvement in endothelial 
function directly translates into improved outcome. In the future, however, 
practitioners may use brachial artery FMD to assess response to drug therapy and to 
individualize patient risk factor modification programs. Further studies are needed to 
determine whether the methodology is sufficiently reproducible and whether 
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biological variability is sufficiently low to make assessment of FMD a clinically 
useful measure of cardiovascular risk on an individual or group basis. To that end, 
the methodology will need to mature, with formal opportunities for training, 
certification and continuing medical education, as currently exist for other 
cardiovascular testing modalities.  
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FUTURE DIRECTIONS 
 Ultrasound assessment of brachial artery FMD has yielded important 
information about vascular function in health and disease, yet several new 
approaches and technological advances have emerged. Most prior studies examined 
FMD at a single time point, typically 1 min after cuff release. This practice evolved 
from the observations that the maximal dilator response occurs at approximately 1 
min in healthy subjects (111) and that the necessity for manual acquisition and 
measurement placed a practical limit on the number of image frames that could be 
analyzed. Commercially available technology now makes it possible to acquire 
multiple images of the brachial artery automatically using the ECG signal as a 
trigger and to measure arterial diameter automatically using computer-based edge 
detection techniques. This approach allows investigators to examine the entire time 
course of brachial dilation in response to reactive hyperemia , the true peak 
response, the time to peak and the overall duration of FMD as discussed in the 
previous text. The time course and extent of brachial expansion within a single 
cardiac cycle, possibly reflecting vessel compliance, can be examined. In the carotid 
artery, compliance has been shown to correlate with cardio- vascular risk (112). 
About 70% of the dilation observed 1 min after cuff release is attributable to NO 
synthesis. 
 Further studies are needed to evaluate other vasoactive mechanisms and to 
determine whether various disease states influence the kinetics and/or extent of 
FMD. Careful examination of the vasodilator response to NTG provides another 
potential avenue for investigation. Although most studies have detected little effect 
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of disease states on this response, there is evidence that cardiovascular risk factors 
might impair the vasodilator response to NTG, especially when a dose-response 
curve is measured. These findings are consistent with experimental studies 
demonstrating that inactivation of NO by reactive oxygen species is an important 
mechanism of vascular dysfunction. Further information about the causes of 
vascular dysfunction and the response to interventions may be gained by examining 
the response to a sub maximal dose of NTG or a series of NTG doses. The effect of 
disease states and/or interventions on the blood flow response to cuff occlusion 
(reactive hyperemia) is under explored. Current technology limits the utility of 
spectral Doppler to reproducibly assess changes in flow, which might provide useful 
information about endothelial function of the microvasculature. 
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CONCLUSION 
1) Endothelial dysfunction is present in SLE patients even in the absence of 
traditional cardiovascular risk factors. 
2) FMD using vascular ultrasonography on brachial artery represents a non-
invasive, reproducible and cost effective tool for the assessment of 
endothelial dysfunction. 
3) Impaired flow mediated dilatation of brachial artery may be an early 
physiological feature of endothelial dysfunction and may precede the 
anatomical increase in carotid intimal thickness.  
4) FMD of brachial artery has significant negative correlation with disease 
activity and antidsDNA antibody. 
5) Future prospects of FMD technique include  
a) early screening module for endothelial dysfunction and to start on drugs 
with  pleotrophic effect like statins, ACE inhibitors and Aspirin. 
 b) serial screening method to ascertain improvement while on treatment with       
immunosuppressive agents and vasodilators.   
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ABBREVIATIONS 
 SLE                    Systemic lupus erythematosus 
 FMD                      Flow-mediated vasodilatation 
 CVD                      Cardiovascular disease 
 IMT                       Intima-media thickness  
 LAI                        Lupus activity index 
 EDD                      Endothelial dependent vasodilatation  
 BMI                       Body mass index 
 SLEDAI                SLE Disease Activity Index   
 SLICC                   Systemic Lupus International Collaborating Clinics  
 ESR                       Erythrocyte sedimentation rate 
 CRP                       C Reactive protein 
 ANA                      Anti nuclear antibody 
 Anti dsDNA        Anti double stranded DNA 
 aCL                       Anticardiolipin antibody  
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PROFORMA 
 
NAME:                                    AGE/SEX:                                 OP/ IP No:                           
 
RCC No    : 
 
ADDRESS:                                                                        OCCUPATION: 
 
 
H/O PRESENT ILLNESS:                           TOTAL DURATION OF ILLNESS  
             
Fever                                  Malaise                                    Fatigue   
                                                      
Malar rash                          Discoid lesion                       Oral ulcer                            
 
Alopecia                             Photosensitivity   
 
Purpura                              Raynaud’s                               Gangrene    
 
Joint Symptoms                          
 
Myalgia                              Weakness                                 Headache                                 
 
Visual sym                         Mood                                     Seizures      
                                                                                                
Chest pain                          Palpitation                               Dyspnoea 
 
Syncope                              Pedal edema  
Cough                                 Expectoration                          Hemoptysis                              
 
Hematuria                           Oliguria                             Facial puffiness                                            
 
OTHERS 
 
PAST HISTORY:    
                                                                         
PERSONAL HISTORY:    
                                           
TREATMENT HISTORY: 
 
PHYSICAL EXAMINATION: 
 
Fever                Anaemia        clubbing         cyanosis      LN       PE      JVP          
 
MUCOCUTANEOUS  
 
OTHERS 
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PULSE                                          BP                                             RR 
CVS                                                     RS                                                  ABDOMEN 
 
 
 
CNS                                              Fundus:                                          MSS: 
 
 
 
 
INVESTIGATIONS: 
 
Hb                   TC                   DC                          ESR 1 hr               Platelets                  
BT                   CT                   PT                INR    APTT 
Urea            Cr             Uric acid       Sugar              T.Bilirubin                   
ALT               AST 
SAP                LDH               CPK                    Na    K     HCO 3      Cl 
Lipid profile 
Urine R/E                                                          PCR                               24 hrs protein 
ANA                                                                 Anti dsDNA                   ACL 
LAC                                                               VDRL                           CRP  
Complement                                                   ENA 
 
Renal Biopsy : 
 
ECG                                                                                         CXR PA View 
ECHO                                                                                       Carotid IMT  
 
 
Flow Mediated Dilatation                   Baseline                          FMD                       
 
ASSESSMENT            SLEDAI                                                 SLICC 
 
 
MANAGEMENT 
 
NSAIDS                                                STEROIDS                Pulse                             
Oral 
IMMUNOSUPPRESSANTS                                                    
ANTICOAGULANTS/ANTIPLATELETS        
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SLEDAI 
Systemic Lupus Erythematosus Disease Activity Index 
Descriptor Definition Weighted 
Score 
Seizure Recent onset; exclude metabolic, infectious, or 
drug-related causes 
8 
Psychosis Altered ability to function in normal activity owing 
to severe disturbance in the perception of reality; 
includes hallucinations, incoherence marked by 
loose associations, impoverished thought content, 
marked illogical thinking, and bizarre disorganized 
or catatonic behavior; exclude the presence of 
uremia and offending drugs 
8 
Organic brain 
syndrome 
Altered mental function with impaired orientation 
or impaired memory or other intellectual function, 
with rapid onset and fluctuating clinical features; 
includes clouding of consciousness with reduced 
capacity to focus and inability to sustain attention 
on environment, and at least two of the following—
perceptual disturbance, incoherent speech, 
insomnia or daytime drowsiness, and increased or 
decreased psychomotor activity; exclude metabolic 
infectious and drug-related causes 
8 
Visual Retinal changes from systemic lupus erythematosus 
cytoid bodies, retinal hemorrhages, serous exudate 
or hemorrhage in choroid, optic neuritis (not due to 
hypertension, drugs, or infection) 
8 
Cranial nerve New onset of sensory or motor neuropathy 
involving a cranial nerve 
8 
Lupus headache Severe, persistent headache; may be migrainous, 
unresponsive to narcotic analgesia 
8 
Cerebrovascular 
accident 
New syndrome; exclude arteriosclerosis 8 
Vasculitis Ulceration, gangrene, tender finger nodules, 
periungual infarction, splinter hemorrhages; 
vasculitis confirmed by biopsy or angiogram 
8 
Arthritis More than two joints with pain and signs of 
inflammation (tenderness, swelling, or effusions) 
4 
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Descriptor Definition Weighted 
Score 
Myositis Proximal muscle aching or weakness associated 
with elevated creatine phosphokinase/aldolase 
levels, electromyographic changes, or biopsy 
specimen showing myositis 
4 
Casts Heme, granular, or erythrocyte 4 
Hematuria >5 erythrocytes per high-power field; exclude other 
causes (stone, infection) 
4 
Proteinuria >0.5 g of urinary protein excreted per 24 hr; new 
onset or recent increase of >0.5 g/24 hr 
4 
Pyuria >5 leukocytes per high-power field; exclude 
infection 
4 
New malar rash New onset or recurrence of inflammatory type of 
rash 
4 
Alopecia New or recurrent; patch of abnormal, diffuse hair 
loss 
4 
Mucous 
membrane 
New onset or recurrence of oral or nasal ulceration 4 
Pleurisy Pleuritic chest pain with pleural rub or effusion, or 
pleural thickening 
4 
Pericarditis Pericardial pain with at least one rub or effusion; 
confirmation by ECG or echocardiography 
4 
Low 
complement 
Decrease in CH50, C3, or C4 levels (to less than 
the lower limit of the laboratory-determined normal 
range) 
2 
Increased DNA 
binding 
>25% binding by Farr assay (to more than the 
upper limit of the laboratory-determined normal 
range, e.g., 25%) 
2 
Fever >38°C after exclusion of infection 1 
Thrombocytope
nia 
<100,000 platelets 1 
Leukopenia Leukocyte count <3000/mm3 (not due to drugs) 1 
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SLICC 
Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index for Systemic Lupus Erythematosus 
 
 
Item Score 
Ocular (either eye by clinical assessment)   
Any cataract ever 0, 1 
Retinal change or optic atrophy 0, 1 
Neuropsychiatric   
Cognitive impairment (e.g., memory deficit, difficulty with 
calculation, poor concentration, difficulty in spoken or written 
language, impaired performance level) or major psychosis 
0, 1 
Seizures requiring therapy for 6 mo 0, 1 
Cerebrovascular accident ever (score 2 if >1) 0, 1, 2 
Cranial or peripheral neuropathy (excluding optic) 0, 1 
Transverse myelitis 0, 1 
Renal   
Estimated or measured glomerular filtration rate <50% 0, 1 
Proteinuria >3.5 g/24 hr 0, 1 
or End-stage renal disease (regardless of dialysis or transplantation) or 3 
Pulmonary   
Pulmonary hypertension (right ventricular prominence, or loud P2) 0, 1 
Pulmonary fibrosis (physical and radiographic) 0, 1 
Shrinking lung (radiograph) 0, 1 
Pleural fibrosis (radiograph) 0, 1 
Pulmonary infarction (radiograph) 0, 1 
Cardiovascular   
Angina or coronary artery bypass 0, 1 
Myocardial infarction ever (score 2 if >1) 0, 1, 2 
Cardiomyopathy (ventricular dysfunction) 0, 1 
Valvular disease (diastolic murmur, or systolic murmur >3/6) 0, 1 
Pericarditis for 6 mo or pericardiectomy 0, 1 
Peripheral vascular   
Claudication for 6 mo 0, 1 
Minor tissue loss (pulp space) 0, 1 
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Significant tissue loss ever (e.g., loss of digit or limb) (score 2 if >1 
site) 
0, 1, 2 
Venous thrombosis with swelling, ulceration, or venous stasis 0, 1 
Gastrointestinal   
Infarction or resection of bowel below duodenum, spleen, liver or 
gallbladder ever, for any cause (score 2 if >1 site) 
0, 1, 2 
Mesenteric insufficiency 0, 1 
Chronic peritonitis 0, 1 
Stricture or upper gastrointestinal tract surgery ever 0, 1 
Chronic pancreatitis 0, 1 
Musculoskeletal   
Muscle atrophy or weakness 0, 1 
Deforming or erosive arthritis (including reversible deformities, 
excluding avascular necrosis) 
0, 1 
Osteoporosis with fracture or vertebral collapse (excluding avascular 
necrosis) 
0, 1 
Avascular necrosis (score 2 if >1) 0, 1, 2 
Osteomyelitis 0, 1 
Tendon rupture 0, 1 
Skin   
Scarring chronic alopecia 0, 1 
Extensive scarring of panniculus other than sculp and pulp space 0, 1 
Skin ulceration (excluding thrombosis for >6 mo) 0, 1 
Premature gonadal failure 0, 1 
Diabetes (regardless of treatment) 0, 1 
Malignancy (exclude dysplasia) (score 2 if >1 site)  
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